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ABSTRACT 
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterised by persistent 
synovitis, systemic inflammation and autoantibodies. RA has a complex aetiology with the 
involvement of genetic factors and environmental triggers, and their interactions. The inherited risk 
for RA is mostly attributed to multiple gene loci, of which the largest contribution is made by the 
major histocompatibility complex (MHC), also known as the human leukocyte antigen (HLA) genes, 
in particular linked to the MHC class II region. Shared epitope (SE) comprises a small part of the 
extensive MHC class II polymorphisms, and has been identified as the strongest genetic risk factor 
with each allele being associated with approximately a 2-fold increased RA risk. Cigarette smoking is 
the best-known environmental trigger and also increases RA risk approximately 2-fold. A profound 
SE–smoking interaction effect has been well described among different populations. The aim of the 
current thesis is to further characterise and quantify this gene–environment interaction, specifically: 1) 
to identify more gene–environment interaction signals using genome-wide materials; 2) to further 
explore the synergistic effect by identifying the interacting components (e.g. which chemical 
component in cigarette smoke triggers RA, the nicotine or the particles?); 3) to determine which 
amino acid positions of MHC class II loci interact with smoking, the traditional SE positions at HLA-
DR or other regions such as HLA-B and HLA-DPB; and 4) to evaluate present understanding of the 
familial risk and heritability of RA, taking into account all the currently identified risk factors. 
In Study I, we conducted a gene–smoking interaction analysis using the genetic information from the 
Immunochip and genome-wide association studies, in two separate Swedish case–control populations 
(the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study in Stockholm and a cohort 
from Umeå). We found no significant interaction signals outside of chromosome 6, in either anti-
citrullinated protein/peptide antibody (ACPA)-positive or ACPA-negative RA, indicating that HLA 
remains a region of great importance, and well-powered studies with larger sample size are warranted 
to identify new signals. 
In Study II, we performed association analysis between smokeless tobacco (snuff) and RA among 
EIRA subjects. We found that moist snuff use (current or past) was not related to the risk of either 
ACPA-positive or ACPA-negative RA. Analyses restricted to never smokers, or stratified by gender, 
provided similar results. We conclude that the use of moist snuff is not associated with the risk of 
either ACPA-positive or ACPA-negative RA, and the increased RA risk associated with smoking is 
therefore most probably not due to nicotine. 
In Study III, we carried out interaction analysis between heavy smoking and RA-related amino acid 
positions (11, 13, 71, and 74 in HLA-DRβ1, 9 in HLA-B and 9 in HLA-DPβ1) using three separate 
case–control populations (EIRA, the Nurses‟ Health Study (NHS) and a Korean cohort). We found 
significant additive interactions between heavy smoking and the amino acid haplotype at HLA-DRβ1 
in all populations. We further identified key interacting variants at HLA-DRβ1 amino acid positions 
11 and 13, in addition to the traditional SE positions 71 and 74. Our findings suggest that a physical 
interaction between citrullinated auto-antigens produced by smoking and HLA-DR molecules is 
characterised by an HLA-DRβ1 four-amino acid haplotype, primarily by novel positions 11 and 13. 
In Study IV, we determined to what extent familial risk of RA could be explained by established risk 
factors by linking EIRA subjects to nationwide registers. We found that established environmental 
risk factors did not explain the familial risk of either seropositive or seronegative RA to any 
significant degree, and that currently known genetic risk factors accounted only for a limited 
proportion of the familial risk of seropositive RA. This suggests that many risk factors remain to be 
identified, in particular for seronegative RA. Therefore, family history remains an important clinical 
risk factor for RA. 
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1 INTRODUCTION 
Rheumatoid arthritis (RA), the most common inflammatory joint disease, occurs when the 
immune system mistakenly attacks its own tissue. RA is characterised by persistent synovitis, 
systemic inflammation and the presence of autoantibodies.
1-3
 The disease affects 0.5–1% of 
the total population, in a female/male ratio of 2.5–3.0/1.1-3 Estimates have shown that 
approximately 50% of the risk of developing RA is attributable to genetic constitution, of 
which the largest contribution is made by the major histocompatibility complex (MHC), also 
known as the human leukocyte antigen (HLA) loci, in particular the MHC class II (or HLA-
DR) region. Shared epitope (SE), a small part of the HLA-DR, has been comprehensively 
investigated and identified as the RA genetic risk factor of primary impact.
4-6
 The remaining 
disease susceptibility could be largely ascribed to environmental influences, of which 
smoking is the best-known risk factor, with a relative risk of between 1.5 and 2, and with a 
dose–response effect observed in several independent samples.7-11 In addition to the genetic 
and the environmental factors, gene–gene and gene–environment interactions play important 
roles. A profound additive interaction between SE and smoking has been described and 
replicated in different populations.
12-14
 Although all the above-mentioned results have been 
specifically restricted to anti-citrullinated protein/peptide antibody (ACPA)-positive RA, the 
underlying mechanisms remain to be elucidated, and much less is known about ACPA-
negative RA. 
Therefore, during the 4 years of study for this PhD, the gene–environment interactions in RA 
have been further explored in terms of the following questions:  
 Firstly, from a genome-wide perspective, do interaction effects exist between 
smoking and genes outside of the HLA region?  
 Secondly, which components of cigarette smoke contribute to this synergistic effect 
given that smoke is a complex mixture of chemical compounds, including nicotine, 
char and other adjuvants
15
 which have different effects on the immune system?  
 Thirdly, as understanding regarding the HLA region has increased considerably with 
in-depth analysis of amino acids (AAs) through imputation, which AA positions 
could be identified in this interaction effect? Is the interaction effect restricted to the 
traditonal SE positions at HLA-DR, or are other regions such as HLA-DP or/and 
HLA-B involved? 
 Finally, current genome-wide association studies (GWAS) and large epidemiological 
investigations have identified a number of genetic and environmental risk factors in 
addition to smoking and SE; how much in total can these factors explain the RA 
heritability using familial aggregation as an indicator? 
This thesis is based on four studies investigating the gene–smoking interaction as well as the 
proportion of heritability that can be explained by currently identified risk factors in RA. 
Epidemiological methods have been used to conduct these studies. It is hoped that this 
research may provide others with ideas for further novel research in this field. 
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2 BACKGROUND 
2.1 IMMUNE SYSTEM, IMMUNITY AND AUTOIMMUNITY 
The immune system consists of a collection of cells, tissues and molecules that mediate 
immunity, which is defined as resistance to disease, specifically infectious disease. The most 
important physiological function of the immune system is, through coordinated action against 
microbes, to prevent infections and to eradicate those that have become established. 
Moreover, the impact of the immune system goes beyond defence against infectious disease. 
On one hand, the immune system participates in the clearance of dead cells, even in some 
cases eradication of tumours, and in initiating tissue repair. In contrast to these beneficial 
roles, on the other hand, abnormal immune responses can injure cells and induce pathological 
inflammation, causing allergic, autoimmune and inflammatory diseases. In addition, the 
immune system recognises and responds to tissue grafts and newly introduced molecules, 
which provides a barrier to transplantation and gene therapy. 
Host defence mechanisms consist of innate and adaptive immunity. Innate immunity is 
always present in healthy individuals, prepared to block the entry of microbes or rapidly 
eliminate those that enter host tissue. Therefore, the epithelial barriers of the skin usually 
provide the first line of defence in innate immunity. Phagocytes, natural killer cells and 
several plasma proteins, including the proteins of the complement system, attack microbes if 
they do penetrate the epithelium and enter tissues or the circulation. However, innate 
immunity is phylogenetically older than adaptive immunity, recognising structures shared by 
classes of microbes, and therefore has lower specificity. The defence against infectious 
microbes, especially those that are pathogenic in humans, requires a more specialised and 
powerful adaptive immune system, which consists of lymphocytes and their products 
(antibodies). Lymphocytes express receptors that specifically recognise a much wider variety 
of molecules produced by microbes as well as non-infectious substances (antigens). There are 
two types of adaptive immunity: humoral immunity mediated by antibodies that are produced 
by B cells mainly neutralises and eliminates microbes that are found outside host cells, and 
cell-mediated immunity mediated by T lymphocytes provides defence against microbes that 
live and divide inside infected cells. The innate and adaptive systems act in both separate and 
cooperative ways; for example, adaptive immune responses often involve cells of the innate 
immune system to eliminate microbes, but also enhance innate immunity. 
There are several crucial properties of the adaptive immune system. It has a vast total 
population of lymphocytes consisting of many different clones, with each clone expressing an 
antigen receptor that is different from all others. This enables the immune system to respond 
to a vast number and variety of antigens, and also ensures that distinct antigens elicit 
responses that specifically target those antigens. Moreover, the adaptive immune system 
remembers the immune responses it has experienced and is capable of inducing more rapid, 
larger secondary immune responses to subsequent encounters with the same antigens. Finally, 
the immune system is able to react against an enormous number and variety of foreign 
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antigens, but it also has developed multiple regulatory systems to avoid re-activities against 
the host‟s own potentially antigenic substances, the so-called self antigens. This 
unresponsiveness to self, known as immunological tolerance, is the ability of the immune 
system to coexist with potentially antigenic self molecules, cells and tissues. 
Immunological tolerance could be interpreted as a homeostatic process maintained by several 
existing mechanisms. Firstly because lymphocyte receptor specificities are generated in an 
unbiased way during the normal process of lymphocyte maturation, all types of receptor 
specificities will be generated irrespective of whether or not they possess the ability to 
recognise self antigen. The thymus (for T cells) and the bone marrow (for B cells) exert 
important functions in restricting the number of maturing self-reactive clones by negative 
selection mechanisms (central tolerance). Despite this negative selection, many self-reactive 
clones have already presented in the organisms. Therefore, several mechanisms must act in 
concert to prevent immune responses to self antigens. Indeed, when lymphocytes specific for 
self antigens encounter the particular antigens in the secondary lymphoid organs or peripheral 
tissues, a number of measures will be implemented to guarantee tolerance. As a result, these 
lymphocytes will undergo changes in their receptors (for B cells) or develop into regulatory 
cells, or anergy or apoptosis will be induced. Any errors or failures that occur during these 
processes will probably influence the maintenance of self-tolerance, and even lead to 
autoimmunity or autoimmune diseases. Multiple molecules have a role in the processes of 
maintaining central and peripheral tolerance, for example: autoimmune regulator is 
responsible for the thymic expression of many peripheral tissue antigens in central T 
lymphocyte tolerance; CD28, cytotoxic T lymphocyte-associated antigen 4 and programmed 
death protein 1 all function to terminate T cell activation, resulting in long-lasting T cell 
anergy; the transcription factor FoxP3 and cytokine transforming growth factor β are required 
for the development of regulatory T cells; and the binding of Fas and Fas ligand may induce 
programmed cell death of both T and B cells. The complexity of both the immune system and 
the maintenance of self-tolerance is a reflection of the genetic complexity of autoimmune 
diseases, to which multiple factors including the inheritance of susceptibility genes and 
environmental triggers contribute. Read the book written by Abul Abbas et al. for a detailed 
description of relevant concepts in basic immunolgy.
16
 
2.2 RHEUMATOID ARTHRITIS 
2.2.1 Clinical Features and Subclassification 
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disorder 
characterised by progressive damage of synovial joints and variable extra-articular 
manifestations.
1-3
 Disease onset is usually insidious with joint symptoms emerging over 
weeks to months and often accompanied by decreased appetite, weakness or fatigue; it can 
take several months before a firm diagnosis can be verified.
1-3
 The major symptoms of RA 
are pain, stiffness and swelling of multiple peripheral joints, in a bilateral symmetrical 
pattern. The clinical course of the disorder can be extremely variable, ranging from mild, self-
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limited arthritis or arthritis-related symptoms to rapidly progressive multisystem 
inflammation with severe morbidity and high mortality.
1-3
 
The incidence of RA increases with age,
2
 but the disease can occur at any age, most 
commonly affecting those aged 40–70 (mean 66) years.17 RA is a common disease, estimated 
to affect about 0.5–1% of the total population worldwide, with a notable low prevalence in 
rural Africa and high prevalence among certain tribes of Native America.
2
 The female/male 
ratio of RA is around 2.5–3.0/1.18 In Sweden, data from both the Swedish National Patient 
Register and the Swedish Rheumatology Quality Register data have indicated a cumulative 
prevalence of RA of 0.77% (women 1.11%, men 0.43%) and an incidence of 41/100000 
(women 56/100000, men 25/100000) up to 2008.
17,19
 Moreover, the lifetime risk of RA 
among adults has been estimated to be 2.7% for women and 1.5% for men, meaning that 1 in 
37 women and 1 in 67 men will develop RA during their lifetime.
17
 As a disease in rapid 
transition, uncontrolled active RA causes joint destruction, functional disability, decreased 
quality of life and several comorbidities, which all account for early mortality.
20
 The RA 
mortality rate has been continuously decreasing in recent decades, during which time 
treatment strategies have fundamentally changed, including an emphasis on early diagnosis 
and early intensive treatment, with the aim of slowing or preventing joint damage and 
remission as the major therapeutic goal.
21
 Several medications have been introduced for 
treating RA: disease-modifying antirheumatic drugs (DMARDs), biologic agents, non-
steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, immunosuppressants and 
others. 
It has been proposed that RA is best considered as a clinical syndrome spanning different 
disease subsets encompassing several inflammatory cascades, which all eventually leading 
towards a common pathway.
22
 It has been increasingly recognised that dividing RA into at 
least two subgroups can account for the potentially different prevention and treatment 
strategies, as well as help to elucidate the distinct aetiology behind each subset.
1,3
 The 
subdivision has been based firstly and classically on the presence or absence of rheumatoid 
factors (RFs), the key pathogenic markers (mainly Immunoglobulin (Ig) M and IgA RF) 
directed against IgG. Later, the classification has been based also on the presence or absence 
of ACPAs. Although in most cases, ACPA and RF status overlap among patients (i.e. ACPA-
positive patients are more likely to be RF positive), ACPAs seem to be more specific for 
diagnosis and better predictors of poor prognosis. Therefore, in addition to the widespread 
classification criteria established in 1987 to define RA based on RF, a new set of criteria was 
developed in 2010 based on ACPAs, which will be discussed below.  
2.2.2 Diagnostic Criteria 
The diagnosis of RA remains criteria guided. The classification criteria that are currently well 
accepted and in widespread international use to define RA are the American College of 
Rheumatology (ACR) 1987 criteria (Table1),
23
 which were derived by attempting to 
distinguish between patients with established RA and those with a combination of other 
definite rheumatologic diagnoses. They are therefore less helpful in identifying patients who 
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could benefit from early treatments, in other words those patients at a stage at which 
evolution of joint destruction can be prevented before initiation of a chronic erosive disease 
course.
24
 The 2010 European League Against Rheumatism (EULAR)/ACR criteria for RA 
classification were subsequently developed (Table2), with the aim of facilitating the 
diagnosis of individuals at an earlier stage of disease.
24,25
 
Table1. 1987 RA classification.23 
Four of these seven criteria must be present. Criteria 1-4 must have present for at least 6 weeks. 
Criterion Definition 
1. Morning stiffness 
Morning stiffness in and around the joints, lasting at least 1 hour 
before maximal improvement 
2. Arthritis of 3 or more joint areas 
At least 3 joint areas simultaneously have had soft tissue swelling 
or fluid (not bony overgrowth alone) observed by a physician. 
The 14 possible areas are right or left PIP, MCP, wrist, elbow, 
knee, ankle, and MTP joints 
3. Arthritis of hand joints 
At least 1 area swollen (as defined above) in a wrist, MCP, or PIP 
joint 
4. Symmetric arthritis 
Simultaneous involvement of the same joint areas (as defined in 
2) on both sides of the body (bilateral involvement of PIPs, MCPs, 
or MTPs is acceptable without absolute symmetry) 
5. Rheumatoid nodules 
Subcutaneous nodules, over bony prominences, or extensor 
surfaces, or in juxtaarticular regions, observed by a physician 
6. Serum rheumatoid factor 
Demonstration of abnormal amounts of serum rheumatoid 
factor by any method for which the result has been positive in 
<5% of normal control subjects 
7. Radiographic changes 
Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must include 
erosions or unequivocal bony decalcification localised in or most 
marked adjacent to the involved joints (osteoarthritis changes 
alone do not qualify) 
 
Table2. The 2010 ACR-EULAR classification criteria for RA.24 
Target population (Who should be tested): Patients who 
    1. have at least 1 joint with definite clinical synovitis (swelling) 
    2. with the synovitis not better explained by another disease 
Classification criteria for RA (score-based algorithm: add score of categories A - D, a score of ≥6/10 is 
needed for classification of a patient as having definite RA); 
A. Joint involvement Score 
    1 large joint 0 
    2-10 large joints 1 
    1-3 small joints (with or without involvement of large joints) 2 
    4-10 small joints (with or without involvement of large joints) 3 
    >10 joints (at least 1 small joint) 5 
B. Serology (at least 1 test result is needed for classification)   
    Negative RF and negative ACPA 0 
    Low-positive RF or low-positive ACPA 2 
    High-positive RF or high-positive ACPA 3 
C. Acute-phase reactants (at least 1 test result is needed for classification)   
    Normal CRP and normal ESR 0 
    Abnormal CRP or abnormal ESR 1 
D. Duration of symptoms   
    <6 weeks 0 
    ≥6 weeks 1 
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2.2.3 Pathogenesis 
In autoimmune diseases, the ability of the immune system to discriminate between self and 
non-self antigens fails. As a result, the individual‟s own cells and tissues are attacked by the 
immune responses, in RA targeting the synovium-lined small joints and subsequently 
involving other organs.
16
  
A number of genes contribute to the development of autoimmunity in general, with particular 
linkages towards the HLA region. The association between HLA alleles and many 
autoimmune diseases has long been recognised and was one of the first indications that T 
cells played an important role in these disorders. Polymorphisms in non-HLA genes are also 
associated with various autoimmune diseases including, for example, protein tyrosine 
phosphatase N22 (PTPN22) in systemic lupus erythematosus and type I diabetes mellitus and 
nucleotide-binding oligomerisation domain-containing protein 2 (NOD2) in Crohn‟s 
disease.
26
 Moreover, environmental triggers such as infection also predispose to 
autoimmunity, with possible mechanisms through inflammation and stimulation of 
expression of co-stimulators or cross-reaction between microbial and self antigens. One such 
example is rheumatic fever, which may occur following a bacterial throat infection. 
Similar to the majority of autoimmune diseases, the aetiology of RA is not fully understood; 
however, it is clear that genetic constitution (with the primary risk factor being the SE on the 
HLA gene), environmental triggers (particularly smoking) and stochastic factors act in 
concert to cause this complex disease. Considerable research has defined several crucial 
cellular players in RA pathogenesis, including T cells, B cells, antigen-presentation cells, 
macrophages and others. Complex interactions among genes, environmental triggers, 
multiple immune cells, cytokines and proteinases mediate the disease.
27,28
 
A potential model taking into account of all these factors has been proposed by Gary 
Firestein.
29
 Briefly, in early RA, the activation of innate immunity probably occurs first. This 
serves as a key pathogenic mechanism for the initiation of synovial inflammation. 
Autoantibodies, such as RF and APCAs, engage with Fc receptors and represent an 
alternative mechanism of the inflammation initiation. Synovial dendritic cells activated by 
toll-like receptor (TLR) ligands can migrate to lymph nodes where activated T cells develop 
towards the T helper type 1 phenotype and, through chemokine receptors, migrate towards 
inflamed synovial tissue. After activation of innate immunity in the joints, the production of 
cytokines and expression of adhesion molecules allows the continued entrance of immune 
cells. In certain conditions, such as the presence of a suitable genetic background, 
lymphocytes may accumulate in inflamed synovium. Under these circumstances, the break in 
tolerance in connection with an HLA-DR background or the T cell repertoire might contribute 
to auto-reactivity towards newly exposed articular antigens. Eventually, long-standing disease 
could develop into a destructive form. Instead of a specific „rheumatoid antigen‟, a wide 
variety of antigens can provide targets and cause both T cell activation and B cell maturation. 
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Hence, a combination of chance and pre-determined events and adaptive immune responses 
directed against autologous antigens are required for the progression of disease. 
Karim Raza et al. proposed a system of six phases in the development of RA: genetic risk 
factors environmental risk factors, systemic autoimmunity, symptoms without clinical 
arthritis, unclassified arthritis and, finally, RA.
30
 As shown in Figure1, the first two phases 
usually influence predisposition towards RA in a combined manner, followed by immune 
abnormalities, and no clinically apparent soft tissue swelling, then the first clinical features of 
synovitis until, eventually, the development of RA. Although it is often assumed that all 
individuals move sequentially through these phases, this might not necessarily be the case. 
Some patients might never experience all phases, some might pass through these phases in a 
different order, and some might even go backwards.
30,31
 The individuals included in our study 
all had RA at phase F, and a majority of them (>85%) had symptom durations of less than 1 
year. 
 
Figure1. The phases (A–E) that an individual may pass through in the transition from health 
to the development of RA (phase F). Adapted from Raza et al..
30
 
2.3 GENETICS IN RHEUMATOID ARTHRITIS 
2.3.1 The Genome, Genes, Mutations and Polymorphisms 
Genetics is the branch of science concerned with genes, heredity and variation in living 
organisms. The hereditary foundation of each living organism (e.g. bacteria, viruses and 
eukaryotes) is its genome, a long sequence of DNA that contains a complete set of hereditary 
information.
32
 The human genome can be structurally divided into 22 autosomal 
chromosomes, the X and Y sex chromosomes and the extra-nuclear mitochondrial genome;
32
 
however, functionally, it is composed of genes, a sequence within the genome that gives rise 
to a discrete product such as a polypeptide or RNA. Each gene is a unit of a single stretch of 
DNA. DNA forms a double helix consisting of antiparallel strands where the nucleotide units 
are connected by 5‟ to 3‟ phosphodiester bonds, with the backbone on the exterior, and purine 
and pyrimidine bases are stacked in pairs in the interior via hydrogen bonds. Adenine (A) is 
complementary to thymine (T), and guanine (G) is complementary to cytosine (C). The 
human genome contains a total of ~3.3×10
9
 base pairs of DNA, where only ~25% of the 
sequences are involved in producing proteins; among them, ~24% are introns (usually 
removed by subsequent RNA splicing) and only a tiny proportion (~1%) is accounted for by 
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the exons that actually code for polypeptides.
32
 This reflects the large degree of DNA with 
unidentified function involving the human genome, which mainly consists of intergenic DNA 
(~22%) and repetitive sequences (~50%), with the latter being further composed of 
transposons, processed pseudogenes, simple sequence repeats, segmental duplications and 
tandem repeats.
32
 Although their functions are generally unclear, the high proportion of the 
genome occupied by these elements might indicate active roles in shaping the genome. The 
number of valid genes is currently estimated to be in between 20000 and 25000, much less 
than originally expected.
32
 
Individual genomes show extensive variations, and all genetic variance originates as 
mutations. Mutations are changes in the sequence of DNA, which can occur spontaneously or 
can be induced by mutagens.
32
 Almost all organisms experience a certain extent of 
spontaneous mutation as the result of random interactions with the environment. Using 
mutagens, it becomes possible to induce numerous changes in any genes thus increasing the 
natural incidence of mutation (i.e induced mutagens). Mutations occur at multiple levels: 
across the whole genome, within a gene, or at a specific nucleotide site. A point mutation is 
the smallest mutation and changes only a single base pair. It can be caused by either chemical 
modification of DNA directly changing one base into another, or by errors during the 
replication of DNA through inserting the wrong base into a polynucleotide. A second 
common form of mutation is known as indels and comprises insertions or/and deletions. 
Indels of one or two base pairs can have the greatest effect if they are within the crucial 
coding sequences, due an inevitable frame-shift. Moreover, indels can affect parts of or even 
whole groups of genes. A possible source of mutations is the many different types of 
transposable elements, which are small DNA entities with mechanisms that enable them to 
move around and insert themselves into new locations. Mutational effects can be beneficial, 
harmful or neutral and can be reversible, depending on their context or location. In general, 
the more base pairs that are involved, the larger the effect of the mutation. Rather than a 
single mutation with great effect, most evolutionary changes are based on the accumulation 
of large numbers of mutations with small effects. Mutation is the main cause of diversity and 
once a mutation is carried with a frequency of more than 1% in the population, it is 
commonly known as a polymorphism. In this study, genetic measurements have been made 
mainly for the identification of single-nucleotide polymorphisms (SNPs), in which a single 
nucleotide (A, T, C or G) in the genome differs among the study population. Of note, only 
mutations in gametes can be transferred to the next generation, and many somatic mutations 
are not inherited. 
Genetic predisposition (also known as genetic susceptibility) describes an increased 
likelihood of developing a particular disease or trait based on a person‟s genetic components, 
resulting from specific genetic variations that are inherited from parents and that contribute to 
the development of a disease with large or small effects. In a small minority of cases, genetic 
disorders can be caused by a single defective gene. Huntington‟s chorea, polycystic kidney 
disease, cystic fibrosis, phenylketonuria and haemophillia are typical examples of such 
disorders (monogenic diseases). They are usually inherited according to Mendel‟s laws as 
 10 
being autosomal dominant, autosomal recessive or X-linked recessive.
33
 In most cases, as for 
many common diseases, such as diabetes mellitus, schizophrenia and hypertension, strong 
genetic components are essential for their occurrence, which means that a large number of 
genes each functioning in a small but significant manner are needed to predispose individuals 
to these outcomes (polygenic diseases).
34,35
 RA is a prototypical multifactorial trait, which is 
caused by the impact of various genes, each influencing the final outcomes to a small extent, 
as well as by interactions between multiple genes and often multiple environmental factors. 
2.3.2 MHC, HLA-DBR1 Gene, SE Hypothesis and RA 
The human MHC is an unusual part of the genome, harbouring the highest density of genes 
(polygenic) with the majority exerting fundamental roles in immunity and having extremely 
high levels of variation (polymorphism) and extensive linkage disequilibrium (LD). The 
MHC was first demonstrated in mice and designated H (histocompatibility)-2 by geneticist 
George Snell, who proposed the idea of using congenic mice (i.e. mice that are bred to be 
genetically identical except at a single locus or genetic region) for the study of cancer. Snell 
quickly discovered that the genetic locus H-2 principally determined the status of acceptance 
or rejection for tumour grafts.
36
 H-2 was subsequently shown to be a complex of many 
closely linked genes with many different alleles occurring at each locus, and was later termed 
the MHC. In the 1950s, Jean Dausset found iso-antibodies against leukocyte antigens in 
blood transfusion recipients, demonstrating a complex genetic system in humans similar to 
the H-2 system of mice.
37
 He showed for the first time that the survival of a grafted kidney 
was correlated with the number of incompatibilities in the HLA system, which means the 
more similar the individuals are at their HLA locus, the more likely it is that they will accept 
grafts from one another. In addition to its immediate application to tissue transplantation, we 
now also know that of all regions identified so far, the MHC region contributes most to the 
immunity-related diseases.
38,39
  
The MHC genes encode the MHC molecules, which have evolved to maximise the efficacy 
and flexibility of their functions, in response to a strong evolutionary pressure to eliminate 
numerous and different types of microorganisms, by binding peptides derived from microbial 
pathogens and presenting them for recognition by antigen-specific T cells. In all species, 
there are two types of MHC molecules, known as class I and class II. Both are membrane 
proteins and contain a peptide-binding cleft at the amino-terminal end. Class I molecules 
consist of an α chain associated with a β2-microglobulin. The amino-terminal α1 and α2 
domains form a peptide-binding groove which is large enough to accommodate peptides of 
8–11 residues. The floor of the peptide-binding cleft is the region that binds peptides for 
display to T cells and the sides and tops are the regions that are in contact with the T cell 
receptor. Class II molecules consist of α and β chains. The amino-terminal α1 and β1 
domains contain polymorphic residues and form a binding groove that is large enough to 
accommodate peptides of 10–30 residues. The β2 domain contains the T cell co-receptor 
CD4-binding site.
16
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MHC class I and class II molecules overlap in a number of characteristics: both classes have 
high levels of polymorphisms, a similar three-dimensional structure and a similar function 
with regard to peptide presentation at the cell surface of CD8
+
 cytotoxic and CD4
+
 helper T 
cells. However, these molecules have distinct tissue distributions. They differ in the types of 
antigenic peptide they present: (mainly) intracellular for MHC class I molecules and (mainly) 
extracellular for MHC class II. In addition, they adopt different pathways. MHC class II 
alleles are strong genetic susceptibility loci for several autoimmune diseases possible owing 
to the peptides they present.
38,40,41
 MHC class I alleles are also associated with some 
inflammatory diseases (i.e. ankylosing spondylitis, psoriasis and others) sometimes in 
interaction with MHC class II alleles (i.e. multiple sclerosis). 
An understanding of the genetic complexity of the HLA region is also helpful to explain the 
role of these molecules in the immune response. The HLA complex is located on 
chromosome 6p21.31, containing over 200 defined genes, and can be divided into three 
classes: class I, class II and class III
38,41
 (see Figure2). 
The class I region contains approximately 20 class I genes coding for the α polypeptide chain 
of class I molecules, of which three classic genes (HLA-A, B and C) are most important. The 
β2-microglobulin of the class I molecule is encoded by genes located on a separate 
chromosome. Class I genes are expressed ubiquitously by almost all somatic cells with 
expression levels varying across tissues.
40
 
The class II region contains genes that code for both the α and β polypeptide chains of the 
class II molecules. Similar to class I genes, three polymorphic genes (HLA-DR, DQ and DP) 
are functionally most important. Class II molecules are mainly constitutively expressed by 
professional antigen-presentation cells, such as dendritic cells, macrophages and B 
lymphocytes,
40
 but their expression can also be induced on many other cells by various 
stimuli. The prominent SE is encoded by genes within this area, the HLA-DRB1 alleles. 
The class III region occupies a transitional area in between the class I and class II regions and 
is not structurally or functionally related to either. Instead of possessing direct immune 
functions, it encodes proteins, such as complement components C2, C4 and factor B, with 
immune response-related functions. A major role of complement components is to interact 
with antibody–antigen complexes and mediate activation of the complement cascade, 
eventually lysing cells, bacteria or viruses. 
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Figure2. Location and organisation of the HLA complex on chromosome 6. Adapted from Jan 
Klein et al.
38
 
The contribution of MHC class II region HLA-DRB1 gene to RA susceptibility has long been 
known and is well documented. Peter Stastny first reported in 1976 that HLA-D (and later 
HLA-DR4) is significantly more common among RA patients than among healthy controls.
42
 
Subsequently, other HLA-DR serotypes, e.g. the HLA-DR1 in Mediterranean populations or 
HLA-DR14 in Native Americans, have also been found to be associated with the disease. It 
has become apparent with the application of modern DNA sequencing techniques since the 
1980s that a common feature of the RA-associated HLA-DR molecules is a shared short 
sequence motif coded by several HLA-DRB1 alleles. Thus, a “shared epitope hypothesis” was 
first established by Peter Gregersen et al. in 1987.
43
 The hypothesis proposes a number of 
specific HLA-DRB1 alleles (haplotypes) that encode a conserved sequence motif of five 
amino acids comprising residues 70–74 in the third hypervariable region of the DRβ1 chain. 
The three homologous amino acid sequence variants are: 1) QKRAA, the most common 
motif among Caucasians, coded primarily by the *0401 allele; 2) QRRAA, the second most 
common motif, coded mainly by *0404, *0101 and *0404; and 3) RRRAA, the least 
common motif, coded by *1001. The specific SE-coding alleles are shown in Table3. 
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Table3. Common amino acid sequences in the DRβ 70-74 region. 
Amino acid 
sequence 
Shared epitope 
motif 
 Coding HLA-DRB1 alleles 
QKRAA + *0401; *0409; *0413; *0416; *0421; *1419; *1421 
DERAA  - 
*0402; *0414; *0103; *1102; *1116; *1120; *1121; *1301; *1302; *1304; 
*1308; *1315; *1317; *1319; *1322; *1416 
QRRAE  - *0403; *0406; *0407; *0417; *0420 
QRRAA  + 
*0101; *0102; *0105; *0404; *0405; *0408; *0410; *0419; *1402; *1406; 
*1409; *1413; *1417; *1420 
RRRAA  + *1001 
RRRAE  - *09; *1401; *1404; *1405; *1407; *1408; *1410; *1411; *1414; *1418 
DRRAA  - 
*0415; *0805; *11011; *11012; *11041; *11042; *1105; *1106; *11081; 
*11082; *1109; *1110; *1112; *1115; *1118; *1119; *1122; *1201; 
*12021; *12022; *12031; *12032; *1305; *1306; *1307; *1311; *1312; 
*1314; *1321; *1601; *1602; *1605 
QARAA - *15; *1309 
QKRGR - *03; *0422; *1107 
This table is adapted from Joseph Holoshitz.
4
 
It has been shown that SE is significantly associated with increased RA risk (especially for 
ACPA-positive RA) from several independent samples in different worldwide populations.
44-
48
 In addition to disease susceptibility, SE-coding alleles have also been found to be linked 
with disease severity and exhibit an allele–dose effect.49 The mechanism underlying the SE–
RA association remains uncertain, but is commonly attributed to the presentation of 
arthritogenic antigens or T cell repertoire selection.
4
  
However, not every RA patient carries SE alleles, and not every SE carrier develops RA, 
indicating that other factors are important in the disease aetiology. Accumulating evidence 
has shown the importance of non-SE risk alleles, located from within the same class II region 
(DPB1, DOB, DQA, DQB) extending to the class I region (HLA-C, HLA-B), independent of 
SE in RA aetiology.
50-55
 As the technology of imputation has developed, a deeper analysis of 
amino acids and classical four-digit alleles of HLA genes has become possible, allowing 
researchers to define more clearly the linkage between HLA region and RA. Soumya 
Raychaudhuri et al.
56
 found the strongest association signal for seropositive RA susceptibility 
at the HLA-DRβ1 amino acid position 11 (or 13, tightly linked to position 11; both positions 
are located in the antigen-binding groove and are outside the well-described SE region) but 
not at the traditional SE positions spanning amino acids 70 to 74. Stepwise conditional 
analyses identified independent but much weaker association signals at positions 71 and 74. 
Moreover, positions at the bases of the HLA-B and HLA-DPB1 molecule grooves were also 
found to confer RA risk. Similarly in East Asians, the same association signal has been 
observed in ACPA-positive RA among Korean and Chinese populations.
57
 Therefore, despite 
serving as the foundation for RA genetics, SE alone is insufficient to explain the HLA-DRB1 
contribution in RA; neither does it fully explain the SE–smoking interaction often observed in 
RA. 
2.3.3 GWAS in RA 
Despite the fact that the most replicable genetic association with RA originates from the most 
complex region of the human genome, it has been estimated, from the extent of sharing of 
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identical HLA alleles by descent within families, that HLA region only accounts for 30% of 
the total genetic effect.
58
 The vast majority of the variance across the genome outside of HLA 
jointly confers the remaining part of the genetic effects. The approaches to measure the genes 
that underlie common disease and quantitative traits often fall broadly into two categories: 
candidate-gene studies and GWAS. 
Before the advent of GWAS, the candidate-gene approach identified a handful of RA 
susceptibility loci outside the HLA region. These loci included: PTPN22,
59
 which remains the 
second strongest RA-associated SNP identified to date, and may act through both T and B 
cell regulatory activities;
60
 protein-arginine deiminase type 4 (PADI4);
61
 cytotoxic T-
lymphocyte protein 4 (CTLA4);
62
 tumour necrosis factor receptor-associated factor 1 
(TRAF1);
63
 and Fc receptor-like protein 3 (FCRL3)
64
 (for a summary, see review by 
Sebastien Viatte et al.).
65
 
In 1996, the common disease/common variant hypothesis was first proposed, assuming that 
much of the genetic variation in a common complex disease is due to common variants of 
relevant small effects.
66,67
 It was argued that these common variants would be more easily 
found by adopting population-based association studies rather than family-based linkage 
analysis, as the later studies are usually well powered to identify rare variants with large 
effects. It was also proposed that all common variants in human genes should be recognised, 
which has been the scientific paradigm for GWAS. 
By 2007, GWAS had become feasible due to several crucial advances: 1) the completion of 
the Human Genome Project providing an accurate blueprint of the human genome sequence; 
2) the initial release of the International HapMap project data, depositing millions of genetic 
markers gathered from four populations (of African, Asian and European ancestry) into the 
public domain; 3) the availability of information on LD patterns, allowing the design of SNP 
chips with efficient capture of common variations using only a subset of genome-wide 
markers (approximately 500000 SNPs); and 4) rapid improvements in SNP genotyping with 
considerably reduced costs. There are several commercially available GWAS chips, differ in 
the way in which the SNPs are selected and the total numbers assayed.
68
 In the area of 
immune-mediated diseases, overlapping aetiological factors have long been suggested owing 
to their shared clinical and immunological features. Therefore, in 2009, investigators of 
eleven distinct autoimmune and inflammatory diseases (with RA being one of them), 
designed the Immunochip, an Illumina Infinium SNP microarray interrogate ~190000 SNPs 
with the major goals as deep replication and fine mapping. The Immunochip has included the 
top 2000 independent meta-GWAS association signal for each disease, as well as all the 
SNPs within confirmed GWAS intervals for each disease, without filtering on spacing and 
LD; and a dense coverage of the HLA and killer immunoglobulin-like receptor loci.
68
 
From 2007, RA GWAS or Immunochip results have been published almost every year in 
populations of both European and Asian descent,
69-79
 bringing the total number of known RA 
risk SNPs to 130 (see Table4). Despite this breakthrough, it is generally believed that 
additional risk alleles for RA remain to be identified. 
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Table4. List of validated RA susceptibility genes. 
Chromosome SNP Genes Populations 
1 rs10494360, rs12746613 FCGR2A Korean 
1 rs2014863 PTPRC Japanese, Korean, European Caucasians 
1 rs2105325 LOC100506023 European Caucasians 
1 rs2228145 IL6R European Caucasians 
1 rs2240336 PADI4 Japanese 
1 rs227163 TNFRSF9 Asian 
1 rs2476601 PTPN22 Korean 
1 rs28411352 MTF1-INPP5B European Caucasians 
1 rs2843401, rs3890745 MMEL1 European Caucasians 
1 rs3753389 CD244 Japanese 
1 rs3761959 FCRL3 European Caucasians 
1 rs7537965 GPR137B Japanese, European Caucasians 
1 rs798000, rs11586238 CD2 European Caucasians 
1 rs883220 POU3F1 European Caucasians 
2 rs10175798 LBH European Caucasians 
2 rs10209110 AFF3 European Caucasians 
2 rs11571302, rs3087243 CTLA4 Japanese 
2 rs11900673 B3GNT2 European Caucasians 
2 rs13426947, rs7574865 STAT4 European Caucasians 
2 rs1980422 CD28 Japanese, European Caucasians 
2 rs34695944, rs13031237 REL European Caucasians 
2 rs6546146, rs934734 SPRED2 Japanese, European Caucasians 
2 rs6715284 CFLAR-CASP8 European Caucasians 
2 rs6732565 ACOXL European Caucasians 
3 rs2062583 ARHGEF3 Japanese, Korean, European Caucasians 
3 rs35677470 DNASE1L3 European Caucasians 
3 rs3806624 EOMES European Caucasians 
3 rs4452313 PLCL2 European Caucasians 
3 rs9826828 IL20RB European Caucasians 
4 rs13142500 CLNK Asian and European Caucasians 
4 rs2664035 TEC European Caucasians 
4 rs2867461 ANXA3 Korean 
4 rs78560100, rs6822844 IL2-IL21 Japanese 
4 rs932036, rs874040 RBPJ European Caucasians 
5 rs39984 GIN1 European Caucasians 
5 rs4867947 LCP2 European Caucasians 
5 rs657075 CSF2 European Caucasians 
5 rs71624119, rs6859212,  ANKRD55 European Caucasians 
6 rs2234067 ETV7 European Caucasians 
6 rs59466457, rs3093023 CCR6 European Caucasians 
6 rs629326, rs394581 TAGAP Japanese, European Caucasians 
6 rs6911690, rs548234 PRDM1 Japanese, Korean, European Caucasians 
6 rs6920220 TNFAIP3 European Caucasians 
6 rs9373594 PPIL4 Asian 
6 rs9378815 IRF4 Asian and European Caucasians 
7 rs3807306, rs10488631 IRF5 European Caucasians 
7 rs4272 CDK6 European Caucasians 
7 rs67250450 JAZF1 European Caucasians 
8 rs1516971 PVT1 European Caucasians 
8 rs4840565, rs2736340 BLK Japanese 
8 rs678347 GRHL2 European Caucasians 
8 rs998731 TPD52 European Caucasians 
9 rs10739580, rs3761847 TRAF1 Korean 
9 rs2812378, rs2812378 CCL21 European Caucasians 
10 rs10795791, rs2104286 IL2RA Japanese 
10 rs12413578 10p14 Asian and European Caucasians 
10 rs12764378, rs10821944 ARID5B Japanese 
10 rs2275806 GATA3 Japanese, European Caucasians 
10 rs2671692 WDFY4 Asian and European Caucasians 
10 rs726288 SFTPD Asian 
10 rs793108 ZNF438 Asian and European Caucasians 
10 rs947474, rs4750316 PRKCQ European Caucasians 
11 chr11:107967350 ATM European Caucasians 
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11 rs3781913 PDE2A-ARAP1 Japanese, European Caucasians 
11 rs4409785 CEP57 European Caucasians 
11 rs4936059 FLI/ETS1 European Caucasians 
11 rs4938573, rs10892279 DDX6 European Caucasians 
11 rs570676, rs540386 TRAF6 European Caucasians 
11 rs595158 CD5 European Caucasians 
11 rs73013527 ETS1 Asian and European Caucasians 
11 rs968567 FADS1-FADS2-FADS3 European Caucasians 
12 rs10683701, rs1678542 KIF5A European Caucasians 
12 rs10774624 SH2B3-PTPN11 European Caucasians 
12 rs12831974 TRHDE Korean 
12 rs773125 CDK2 European Caucasians 
13 rs9603616 COG6 European Caucasians 
14 rs1950897 RAD51B European Caucasians 
14 rs2841277 PLD4 Japanese, Korean, European Caucasians 
14 rs3783782 PRKCH Asian 
15 rs8026898 TLE3 Japanese 
15 rs8043085 RASGRP1 Japanese, Korean, European Caucasians 
16 rs13330176 IRF8 European Caucasians 
16 rs4780401 TXNDC11 European Caucasians 
17 rs12936409, rs2872507 IKZF3 European Caucasians 
17 rs1877030 MED1 Asian and European Caucasians 
17 rs72634030 C1QBP Asian and European Caucasians 
18 rs2469434 CD226 Asian 
18 rs2847297 PTPN2 Japanese, European Caucasians 
19 chr19:10771941 ILF3 European Caucasians 
19 rs34536443 TYK2 European Caucasians 
20 rs6032662, rs4810485 CD40 Japanese, Korean, European Caucasians 
21 rs1893592 UBASH3A European Caucasians 
21 rs2075876 AIRE Japanese, European Caucasians 
21 rs2834512 RCAN1 Japanese, European Caucasians 
21 rs73194058 IFNGR2 European Caucasians 
21 rs9979383 RUNX1 Korean, European Caucasians 
22 rs11089637 UBE2L3-YDJC Asian and European Caucasians 
22 rs3218251, rs3218253 IL2RB European Caucasians 
22 rs4547623 GGA1/LGALS2 Japanese, European Caucasians 
22 rs909685 SYNGR1 European Caucasians 
X chrX:78464616 P2RY10 Asian 
X rs13397 IRAK1 European Caucasians 
 
2.3.4 Imputation 
Despite the tremendous number of genotyped SNPs provided by both the Immunochip and 
GWAS scan, many SNPs have still not been genotyped. Taking into account that RA is 
closely linked with the most complex HLA region, identifying its precise nature and clearly 
defining the linkage remain a challenge. The application of imputation has, however, helped 
to solve this problem to some extent. Imputation is the process of predicting or imputing 
genotypes that are not directly assayed in a sample of individuals, by comparing the sample 
of individuals that has been genotyped to a subset of SNPs with a reference panel that has 
been densely genotyped (or nowadays even sequenced).
80
 The theoretical basis of imputation 
is identical by descent (IBD), indicating that two or more individuals have inherited a 
segment with the same ancestral origin, so that the segments have similar nucleotide 
sequences. This is not difficult to understand because, if traced back long enough, all 
individuals in a finite population are related. Therefore, in samples of unrelated individuals 
but with the same ethnicity, the haplotypes of the individuals over short stretches of sequence 
will be related to each other by being IBD.
80
 Imputation methods attempt to compare the 
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underlying haplotypes of the study individuals to the haplotypes in the reference set, identify 
sharing between the two, and use this sharing to predict missing alleles in the study 
population. Therefore, it is important when performing imputation to employ large, high-
density reference panels that have ancestry close to that of the study population. HapMap 2 
haplotypes and large reference panels from the other consortia have been widely used. The 
algorithms of imputation differ in the way in which specific models are used, but all 
essentially comprise a phasing procedure, after which the haplotypes are compared to and 
modelled as a mosaic of the dense haplotypes in the reference panel (see Figure3). Missing 
genotypes are then imputed through matching. Imputation can be implemented within a 
focused chromosome region, or over the genome. It helps to perform fine-mapping, to 
harmonise data for meta-analysis and to correct genotype errors, which all boost the power of 
the study. 
 
Figure3. The method of genotype imputation. Adapted from Jonathan Marchini et al.
80
 
2.3.5 The Concept of Heritability 
Before considering heritability estimates in RA, it is useful to understand the concept of 
heritability. Here height will be taken as an example to illustrate the relevant factors. 
Assuming in a certain population that body height has been measured in everyone, it is 
reasonable to expect that the measurements would be diverse: some individuals would be 
taller while others would be shorter. Thus the body heights of this particular population could 
be described by a mean (μ) and a variance (σ2) indicating the spread of the set of numbers 
(i.e. variance equal to 0 indicates identical values for the entire sample). A question that 
might be of interest is whether the observed variation in height is due to environmental or 
genetic factors: the nature–nurture debate (which is a simplified way of ignoring the 
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genotype–environment correlation or interaction). According to this idea, the variance could 
thus be divided into two parts, attributed to genotype (σ2G) and environment (σ
2
E); the genetic 
variance could be further subdivided into the variance of additive genetic effects (σ2A, i.e. 
each allele adds some effect to the phenotype), dominant genetic effects (σ2D; of note, all 
effects that are non-additive are considered dominant in this case) and gene–gene interactions 
(σ2I). Therefore the broad-sense heritability (H
2) is defined as σ2G / σ
2
, and the narrow-sense 
heritability (h
2
) as σ2A / σ
2
. In practice, narrow-sense heritability is usually referred to, 
because it is the chief cause of resemblance between relatives and the main determinant of 
selection response (see Figure4). To summarise, heritability is the extent to which differences 
in the phenotypes of a trait can be accounted for or predicted by differences in genes;
81
 that is, 
the additive genetic variation. Gene–gene or gene–environment interactions are not 
considered in this very simplified definition. 
Several misconceptions regarding heritability should be considered. Firstly, heritability 
cannot be applied to an individual person because there will be no variance, therefore it does 
not indicate the proportion attributable to genetic factors for the traits of an individual. 
Secondly, heritability does not reflect the extent of a phenotype that is passed on to the next 
generation; this is only determined by genes. A high heritability implies that most of the 
variation observed is caused by variations in genotype, but it does not mean that the 
phenotype is determined once the genotype is known, nor does it determine how modifiable a 
trait is to environmental influences. Furthermore, it is well known that the heritability of 
human height is 80–90%. This does not mean that 1) height in all individuals is determined 
by 80–90% by genetics and 10–20% by the environment, 2) that environmental intervention 
should not be employed to increase body height as “it does not contribute much” or 3) that by 
removing all the “short genes”, 80–90% of the “short stature” of the population could be 
improved. Finally, heritability varies across populations, thus within-group heritability in 
theory cannot be used to explain between-group differences but, in reality, this is usually 
done because the heritability for some diseases remains stable across the population. 
Heritability can also differ between sexes and with age. See review by Peter Visscher et al. 
for a detailed description of these concepts.
81
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Figure4. Additive variance versus dominant variance: why narrow-sense heritability is most 
commonly referred to? 
Disease status is usually defined in a binary fashion, rather than as a continuous variable. 
When the concept of genetic heritability, which is usually applied to depict variation in 
quantitative traits (such as body height and body weight), is extended to include categorical 
traits (RA versus non-RA), a genetic liability model is generated. It is assumed that there is an 
underlying, unmeasured yet normally distributed continuous liability scale for a phenotype, 
with the presence or absence of the phenotype determined by a threshold. Weight is a good 
example of such a scenario: clinically, individuals could be divided into either obese or non-
obese, however the binary trait is based on the continuous scale of body mass index, which 
serves as the underlying unobserved liability scale. Such liability scales exist in all other 
diseases. Heritability in this case is estimated from the pattern of associations in categorical 
traits measured in first degree relatives (FDRs). 
Traditionally, heritability is estimated from the degree of resemblance between relatives, e.g. 
parents–offspring, siblings and twins. Studies usually adopt simple and balanced designs 
based on families, such as regression functions of offspring on parental phenotypes, 
correlation of full or half siblings and difference in the correlation between monozygotic and 
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dizygotic twin pairs.
81
 These methods are straightforward: the phenotype of the two relatives 
will always be positively correlated as they share genetic causes of the phenotype to different 
extents, depending on their kinships. In addition, the more a trait is aggregated within 
families, the higher the heritability owned by that trait. In the era of genomics with the 
development of high-density genotyping platforms, estimation of heritability in unpedigreed 
populations for complex or medically important traits becomes possible. Genetic markers can 
be used to calculate the relatedness between pairs of individuals and help to estimate 
heritability in a novel way.
81
 
2.3.6 Heritability in RA 
What is the level of heritability in RA? The results of several early twin studies have 
indicated that RA heritability is 40–60%.82-84 In a recent study of 12590 twins, ACPA-
positive RA heritability was calculated to be 41%.
85
 Studies using genome-wide markers 
have estimated the heritability of ACPA-positive RA to be 40–55%.86,87 In a large 
population-based study of FDRs, it was estimated that the heritability of ACPA-positive and 
ACPA-negative RA was ~50% and ~20%, respectively.
6
 There is some variation regarding 
the purported strength of familial aggregation of RA. The results of hospital-based surveys, 
with limited sample sizes and lacking controls groups, have suggested that 7–22% of RA 
patients have one or more FDRs affected by the disease.
88-92
 Studies with representative 
control groups have reported relative risks (RRs) ranging from 1.7 to 4.6.
93-97
 A recent 
register-based study in the Swedish total population found familial odds ratios (ORs) for RA 
of about 3 in FDRs and 2 in second-degree relatives.
6
 
The extent to which identified genetic loci may explain RA heritability has been explored in 
GWAS, and several authors have concluded that identified genetic loci account for about half 
of RA genetic liability,
77,98,99
 or 50–65% and 30–50% of the genetic liabilities of ACPA-
positive and ACPA-negative RA, respectively.
100
 However, identified non-HLA alleles only 
explain 5–14% of seropositive RA heritability.75,77,79,101 It was recently calculated that 
identified variants in the HLA region would explain 12.7% of ACPA-positive RA liability.
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These estimates seem to indicate roughly equal importance of genetic and environmental 
factors for the development of seropositive RA. It appears that for the development of 
seronegative RA, environmental factors are of relatively greater importance than genetics, but 
it should be noted that seronegative RA also harbours greater heterogeneity. Moreover, the 
estimates further imply that identified genetic markers should explain a substantial proportion 
of the familial aggregation of RA. 
2.4 ENVIRONMENTAL FACTORIS IN RHEUMATOID ARTHRITIS 
Emerging data suggest that the systemic inflammation and autoimmunity in RA begin long 
before the onset of detectable joint inflammation. Environmental factors might play an 
important role as the first triggers of RA at sites distant from the joints (i.e. the lung, oral 
cavity and gut) where it is believed that inflammation originates.
102
 The established 
environmental risk factors for RA will be introduced briefly in this section. 
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2.4.1 Smoking 
So far, the most clearly demonstrated environmental risk factor of major importance for RA 
is smoking, and this has been consistently replicated in a number of independent 
epidemiological investigations in a variety of populations of different ethnicities.
7-11,103,104
 
Two recently published meta-analyses have demonstrated that ever, current and past smokers 
carry an OR of 1.9 (95% confidence interval (CI): 1.6–2.3), 1.9 (95% CI: 1.5–2.3) and 1.8 
(95% CI: 1.3–2.3) for the risk of developing RA, respectively,105 and that the increased risk 
effect is dose dependent, where RA risk is elevated by smoking by 26% for 1–10 pack-years, 
94% for 20–30 pack-years and 107% for >40 pack-years.106 The effect of smoking has been 
found to be restricted to ACPA-positive RA.
10,103
 Less is known about the impact of smoking 
cessation on the future risk of RA, with a few studies finding a reduction, but not elimination, 
in risk after 10–20 years of smoking cessation.7-9 
Cigarette smoke is a complex mixture consisting of various chemical compounds, e.g. 
nicotine, char and adjuvants, each of which has a different function on the immune system.
15
 
Some constituents such as char may act as adjuvants and enhance both innate and adaptive 
immunity by activation of antigen-presenting cells
107
 whereas nicotine may suppress 
inflammation through relatively well-investigated mechanisms.
108
 Therefore it is of interest to 
investigate which substances in inhaled smoke increase RA risk: the particles or the nicotine. 
2.4.2 Other Airway Exposures 
In addition to smoking, another well-characterised inhalation exposure for RA is silica, which 
has long been known to be an occupational hazard of working in certain industries. A 
moderate risk effect of silica dust has been observed for ACPA-positive (OR: 1.6) and RF-
positive RA (OR: 1.9).
109-111
 An additive interaction between silica and smoking has also 
been reported, with an OR of 7.36 among silica-exposed current smokers and an attributable 
proportion due to interaction of 60%, in the aetiology of ACPA-positive RA.
110
 Other 
respiratory factors, such as mineral oil, air pollution and organic solvents, were also reported 
to increase RA risk with marginal significance.
112-114
 
2.4.3 Alcohol  
A significant inverse association between alcohol consumption and RA risk for both men and 
women has been observed in a number of case–control and cohort studies.115-119 Compared 
with individuals who do not drink any alcohol, a 30–40% dose-dependent decreased risk has 
been identified among moderate drinkers. The adverse impact has also been demonstrated in 
terms of disease severity.
117
 A possible explanation of the underlying mechanism could be 
that alcohol exerts effects on both the hormonal and the immunological systems to 
downregulate immune response, suppress the synthesis of proinflammatory 
cytokines/chemokines and elevate serum oestradiol concentrations.
115
 A complementary 
molecular explanation has been suggested from studies on experimental arthritis in rodents 
where alcohol reduces inflammation and arthritis incidence and severity through inhibition of 
the NFKB pathways.
120
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2.4.4 Other Lifestyle-related Factors 
Several lifestyle-related factors associated with moderate risk of RA have been well 
established, in addition to cigarette smoking and alcohol consumption. Being 
overweight/obese is associated with an increased RA risk, a worse long-term disease 
outcome, and a poor response to certain treatments.
121-123
 This association might be due to the 
immunomodulating and proinflammatory properties of adipose tissue. Dietary habits such as 
low or no fatty fish consumption are also associated with increased RA risk.
124-126
 
Furthermore, low socioeconomic status and high levels of personal and neighbourhood 
deprivation have been linked to increased RA risk.
127,128
 Finally, hormonal and reproduction-
related factors such as parity, breastfeeding and oral contraceptive use are important RA-
related factors among women, although inconclusive results have been reported.  
2.5 GENE–ENVIRONMENT INTERACTIONS IN RA 
2.5.1 Concept of Interaction 
In many settings, the effect of one exposure may depend in some way on the presence or 
absence of another exposure; in other words, there is an interaction between the two 
exposures. The term “interaction” has different meanings which easily generates confusion. 
The interpretation thus largely depends on subjective opinions. Terms such as “effect 
modification”, “effect measure modification”, “synergism” and “antagonism” have all been 
used to describe interaction.
129
 Interaction can occur between genetic and environmental 
exposures, as well as between two (or more) environmental exposures, or (two or more) 
genetic exposures. 
From a statistical point of view, interaction refers to the necessity of adding a product term in 
a statistical model in order to “fit the data well”.130 The product terms can be included in 
different types of models. The two most commonly used statistical models in epidemiology 
are logistic regression and Cox regression, which are inherently multiplicative (they are 
implicitly exponential). Thus, the presence of an interaction term in such a model implies 
departure from multiplicativity; whereas the inclusion of an interaction term in a linear 
regression model implies departure from additivity. Therefore, whether statistical interaction 
reflects departure from multiplicativity or additivity depends largely on the selected models. 
Because the vast majority of epidemiological analyses are based on multiplicative models, 
most results utilise and reflect the multiplicative scale. Moreover, statistical interaction may 
be applied solely on the basis of concern for statistical convenience, e.g. to fit the data best, 
without any consideration for biological mechanisms. The strengths of statistical interaction 
are the simple description of observed phenomena and often with prediction as a related goal, 
which do not need to be linked with biological inference (e.g. multivariate risk predictive 
functions).
131
 
In the field of epidemiology, it has long-been debated whether the scale of interaction should 
be determined by the best-fit statistical model considering only the statistical convenience 
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and simplicity, or whether it should be assessed in a model that corresponds well to the 
biological process to also incorporate biological accuracy. 
Biological interaction refers to the mutual or co-dependent operation of two or more causes to 
produce the disease, which is the case for most diseases. It has been argued that the additive 
scale is more appropriate to evaluate biological interaction, and that it fits with the sufficient-
component concept of causality, as suggested by Rothman.
132
 Sufficient causes could be 
interpreted as minimal sets of actions, events or states of nature that together initiate a process 
that inevitably results in the outcome.
132
 For a particular outcome there would be many 
sufficient causes, each involving various component causes. If two independent causes are 
both the components of the same sufficient cause, then they participate together and a 
synergistic effect is presented.
133
 Additive interaction could thus be defined as the synergistic 
effect of two contributory causes of a disease exceeding the sum of their independent 
effects.
131
 Often the additive interaction is of greatest public health importance in that 
identification of all the components of a given sufficient cause is unnecessary for prevention; 
blocking the causal role of one component renders the joint action of the other component(s) 
insufficient, and thus prevents the effect. Three measures have been proposed to assess 
additive interactions: the relative excess risk due to interaction (RERI), the attributable 
proportion due to interaction (AP) and the synergy index (S).
134
  
Assuming that two exposures contribute to the disease, and RR00 is the relative risk of 
individuals with none of these exposures, RR01 and RR10 are the risks of individuals with 
either one exposure and RR11 is the risk of individuals with both exposures, the three 
measures can be calculated as follows: 
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2.5.2 SE–Smoking Interaction in RA 
A striking gene–environment interaction between smoking and SE was first reported by 
researchers from Sweden (our group). This work demonstrated a strong interaction effect 
only associated with seropositive RA.
14
 Furthermore, the additive interaction suggested a 
biological pathway to disease onset. These findings have been replicated and expanded in 
subsequent studies.
135-138
 In an attempt to identify specific mechanisms by which SE and 
smoking trigger RA, bronchoalveolar lavage (BAL) fluid has been examined from healthy 
non-smokers, health smokers and smokers with inflammatory lung diseases. It was found that 
both the expression of PAD2 enzyme in human lungs and the proportion of citrulline-positive 
BAL cells were elevated by smoking, whereas citrullinated cells were not present (to the 
same degree as smokers) in non-smokers.
13,139
 These findings led to the hypothesis that 
smoking induces citrullination of proteins in the lungs, as well as the prevalence of inducible 
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bronchus associated lymphoid tissue. Both mechanisms can result in a production of RF and 
ACPA. The antibodies, together with a correct genetic background (SE and PTPN22) and 
another trigger in the synovium, lead to the development of RA. In addition to SE, smoking 
interacts with several well-characterised loci, including TNFAIP3, CTLA4, STAT4, PTPN22, 
TRAF1/C5, PADI4, GSTT1, GSTM1, HMOX1 and EPXH1.
140-142
 However, these previous 
studies of the interplay between smoking and genetics used the candidate gene approach 
instead of examining the whole genome, and the results were mostly restricted to one 
population. 
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3 AIM  
3.1 OVERALL AIM 
To study the gene–smoking interaction in the aetiology of RA. 
3.2 SPECIFIC AIM 
Study I: To investigate the cigarette smoking–SNP interaction in RA by using markers from 
both GWAS and Immunochip materials, and to identify novel variations within and outside 
the HLA region. 
Study II: To explore whether exposure to nicotine is associated with RA risk, using snuff 
consumption as an indicator of nicotine exposure. 
Study III: To clearly define the interaction between cigarette smoking and HLA amino acid 
positions in seropositive RA, with the new HLA-DRβ1 amino acid model. 
Study IV: To test how much of the RA familial risk can be explained by currently established 
genetic and environmental risk factors. 
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4 MATERIALS AND METHODS 
Three of the four studies included in the current thesis have incorporated more than one 
independent dataset; an overview has been presented in Table5. Briefly, four datasets and two 
nationwide registers were involved. Study I comprised a discovery phase (EIRA) and a 
replication phase (Umeå) implemented in two separate datasets; Study II was based on EIRA 
alone; Study III was carried out in parallel in three populations (EIRA, NHS and a Korean 
cohort); and Study IV was largely based on EIRA with linkage to two nationwide registers. 
All the studies were of case–control design with exposure and outcome variables 
dichotomised. Therefore, logistic regression was primarily employed in terms of statistical 
models. The two main analyses, an association and an interaction analysis (additive and 
multiplicative, respectively), investigated RA overall as well as RA subsets according to 
serotypes. All the studies were approved by the relevant regional ethics committees and all 
subjects provided informed consent to participate. 
4.1 MATERIALS 
4.1.1 Study Design and Populations 
The EIRA Study  
EIRA, a population-based case–control study initiated in 1996, includes incident RA cases 
and controls aged 18–70 years recruited from defined (southern/central) regions of Sweden. 
EIRA is actively enrolling new subjects. The data based on the first version of the EIRA 
questionnaire during the recruitment period between 1996 and 2006 is defined as EIRA I. 
From 2006, a second recruitment period with a modified questionnaire was initiated and 
EIRA II denotes the data from this second phase. Cases were patients who received a 
diagnosis of RA according to the 1987 ACR criteria by rheumatologists in the study area. The 
aim of EIRA is to identify incident cases in the study database as soon as possible after the 
onset of disease. Therefore the median symptom duration for more than 90% of EIRA cases 
is 10 months. Controls were randomly selected, matched for age, gender and residential area 
with the cases, from a continuously updated national register. One control (two controls since 
2006) was selected per case. Details of the study design have been described elsewhere.
11
 
Subjects filled out a self-administered questionnaire at baseline, and blood samples were 
collected for further genetic or serological tests. 
The Umeå Study 
The Umeå study population was based on a nested case–control study established through 
two population-based cohorts (the Northern Sweden Health and Disease Study cohort, and 
the Maternity cohort of Northern Sweden) in the four northern-most counties of Sweden. All 
eligible patients were diagnosed with early RA according to the 1987 ACR criteria, and were 
consecutively included by rheumatologists at the Department of Rheumatology, University 
Hospital Umeå. Controls were randomly selected from the Medical Biobank of northern 
Sweden, matched for age and gender with the cases. Four controls were selected per case. 
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Details of the study database have been reported elsewhere.
143
 Subjects filled out a self-
administered questionnaire at baseline, and provided blood samples for further genetic or 
serological measurements. 
The NHS 
The NHS was established in 1976 in the USA. Registered nurses, aged 30 to 55 at the time, 
who lived in the 11 most populous states and whose nursing boards agreed to contribute to 
the study, were enrolled in the cohort. These nurses were required to respond to the baseline 
questionnaire, and were selected for prospective follow-up. Every 2 years they receive a 
follow-up questionnaire with questions about diseases and health-related topics (e.g. 
smoking, hormone use and menopausal status). Blood samples were collected to identify 
potential biomarkers. The NHS subjects included in the current thesis were from a nested 
case–control study based on the prospective NHS. Women who reported RA were screened 
for RA symptoms; chart review confirmed RA according to the 1987 ACR criteria. Healthy 
control subjects were selected and matched with the cases at the index date of diagnosis by 
age, menopausal status and post-menopausal hormone use. 
The Korean Study 
The Korean cases were recruited from Hanyang University Hospital for Rheumatic Diseases 
in Seoul, Korea, and were all ACPA positive. The controls were healthy volunteers recruited 
partly from the hospital (healthy hospital staff), and partly from recruiting campaigns. 
Smoking information was retrospectively recorded as never, past or current smoking and, for 
smokers, pack-years of smoking at RA onset.  
The Swedish Nationwide Registers 
The index persons in the Swedish Multi-Generation Register are Swedish residents born in 
1932 or later, and registered as alive in 1961. The register identifies the parents of the index 
persons.
144
 With information available on more than 9 million individuals, the coverage is 
good from the 1940s and almost complete for those born in or after 1968. FDRs of EIRA 
subjects were ascertained through this register. 
The Swedish Patient Register contains information about inpatient treatment since 1964 
(complete nationwide coverage from 1987), and outpatient visit diagnoses from non-primary 
care since 2001.
145
 RA was defined as having more than two diagnoses of RA, with at least 
one assigned by specialists in rheumatology or internal medicine. Validation studies have 
demonstrated that approximately 90% of such individuals, whether admitted to hospital or 
diagnosed during an outpatient visit, fulfill the 1987 ACR criteria.
146
 RA occurrence among 
the FDRs of EIRA subjects was assessed through this register. 
4.1.2 Genetic and Biological Measurements 
Enzyme-linked Immunosorbent Assay 
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Serum ACPA status was measured using an enzyme-linked immunosorbent assay 
(ImmunoscanCCPlus, Euro-Diagnostica). Cut-off for positivity was 25 U/ml. RF status was 
assessed based on the patients‟ history of seropositive or seronegative RA, according to the 
10
th
 revision of the International Classification of Disease codes. Both ACPA and RF data 
were available for EIRA and Umeå study participants, whereas only RF was available in 
NHS. 
SE Genotyping 
The genotyping procedures for HLA-DRB1 alleles were performed in blood DNA samples by 
sequence-specific primer-polymerase chain reaction. For the HLA-DRB1 low-resolution kit, 
an interpretation table was used to determine the specific genotype according to the 
manufacturer‟s recommendations. HLA-DRB1*01 (except DRB1*0103), *04 and *10 were 
classified as SE alleles. 
Immunochip 
Immumochip was used as a source of genetic markers, as well as the material for imputation. 
The EIRA Immunochip scan included 195586 genetic markers from 5043 samples. Data 
were filtered on the basis of both SNPs and individuals (SNP genotype call rates >95% 
completeness in both cases and controls; minor allele frequency >0.01 in both cases and 
controls; and Hardy-Weinberg equilibrium p-value >1×10
-5
 in controls; in addition, subjects 
with more than 5% missing genotypes, evidence of relatedness and non-European ancestry 
were excluded). 
Population stratification was controlled using the principal component approach (PCA) 
implemented in software EIGENSTRAT. The high-density genotype data provided by the 
international HapMap project release III for four reference populations, CEPH trios from 
Utah with Northern European ancestry, Yoruba trios from Ibadan Nigeria, unrelated Japanese 
individuals from Tokyo and unrelated Han Chinese individuals from Beijing, were 
downloaded and used as the reference sample. PCA analysis was performed for the EIRA 
sample combined with the reference sample at the same available SNPs (n=44863). Outliers 
were identified and deleted. This trimming step was iteratively executed, removing 17 
outliers in five iterations. After quality control (QC), a total of 133648 SNPs and 4337 
participants (1590 ACPA-positive RA patients, 891 ACPA-negative RA patients and 1856 
control subjects) were included. 
After similar QC, Immunochip data were available for 1859 individuals (614 ACPA-positive 
and 271 ACPA-negative RA patients, and 974 control subjects) in the Umeå study, and 598 
individuals (235 seropositive RA patients and 363 control subjects) in the NHS study. 
GWAS Scan 
The Immunochip primarily targets the known immunity-related genes, and is therefore not 
truly “genome wide”. Thus EIRA GWAS data, obtained using the Illumina 300K chip and 
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available for 1147 ACPA-positive and 774 ACPA-negative RA cases and 1079 controls for 
301171 markers after QC, were included as another source of genetic markers. 
Imputation 
The procedure for HLA imputation was performed using HLA2SNP software according to 
the manufacturer‟s instruction manual. Immunochip data were used, together with a publicly 
released European reference panel generated by the Type1 Diabetes Genetics Consortium 
(T1DGC). This reference dataset contains SNPs selected to cover the entire MHC region and 
HLA alleles at four-digit resolution in 2767 unrelated individuals of European descent. 
Missing genotypes in the Immunochip sample, as well as the subsequent amino acids, were 
imputed using those matching haplotypes in the reference panel. For the EIRA and NHS 
datasets, the classical alleles and amino acids of HLA-DRB1 were imputed. For the Umeå 
dataset, only the SE alleles were imputed. The concordance rate between imputed SE and 
genotyped SE at two-digit resolution were 97.4%, 97.3% and 93.8% for the Umeå, EIRA and 
the NHS cohorts, respectively. 
4.1.3 Environmental Factors 
Exposure to cigarette smoking was based on self-reported questionnaires. Ever smokers were 
defined as individuals who reported that they smoked or had previously smoked cigarettes 
(current smokers and former smokers); never smokers were defined as those who reported 
that they had never smoked cigarettes. Subjects who smoked pipes or cigars were excluded, 
thus the ever smoker group was restricted to cigarette smokers. Only exposure data up to the 
index year (the year in which first RA symptoms occurred in cases, and the same year for the 
corresponding controls) was used. Pack-years of smoking were calculated with 1 pack-year 
equivalent to smoking 20 cigarettes per day for 1 year, and were categorised as below/equal 
to versus above 10 pack-years. 
Exposure to snuff use was based on information from a self-reported questionnaire. The 
relevant section contains two questions regarding snuff use: 1) Are you currently using snuff? 
Yes/No; and 2) If not, have you previously used snuff? Yes/No. Ever snuff users were 
defined as individuals who reported both current and former snuff use; never snuff users 
reported that they had never used snuff. 
Other lifestyle-related factors were categorised adopting the same categorisation as in our 
previous publications. Briefly, ever drinking was defined by questions about present alcohol 
consumption as well as previous habitual consumption, including both current and former 
drinkers. Total alcohol consumption was calculated based on drinks per week (with one drink 
equal to 16 g alcohol). Ever parious was only relevant among women and was defined as 
having ever given birth. Individuals who were construction workers were included as silica 
exposed; and whose work involved either rock drilling or stone crushing in particular were 
considered to have been exposed to high levels of silica. Body mass index was calculated 
based on self-reported height and weight. Fatty fish consumption was categorised into 
frequent (at least 1–2 times/week), less frequent (at least 1–2 times/month but less than 1-2 
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times/week) and never/seldom consumption. Level of education was determined through 
linkage to the Swedish Register of Education, and was classified as ≤9, 10–12 and 12+ years. 
4.2 STATISTICAL ANALYSIS 
4.2.1 Study I 
Exposures: Cigarette smoking status (ever/never), genetic markers from the Immunochip 
(risk allele/referent allele) and genetic markers from the GWAS (risk allele/referent allele).  
Outcomes: ACPA-positive and ACPA-negative RA. 
Statistical analysis: Additive and multiplicative interactions between smoking and SNPs in 
the risk of developing ACPA-positive and ACPA-negative RA. 
We first calculated the AP together with its 95% CIs to evaluate the additive interaction 
between smoking status (never/ever) and the Immunochip markers, adjusted for the matching 
factors (age, gender and residential area). A Bonferroni corrected p-value for the AP of less 
than 0.05 (corresponding to a genome-wide p-value threshold of 3.74×10
-7
) was set as the 
threshold for significance. Three genetic models (dominant, recessive and co-dominant 
models) were applied. To maintain the stability of our results, smoking–SNP pairs with a 
minimum cell frequency of less than 5 were considered unreliable and were not included in 
the final results regardless of p-values. We then performed the same analysis among those 
significant smoking–SNP pairs with adjustment of copies of SE, to identify markers 
independent of SE. Each step was replicated in the same way using the data from the Umeå 
study. We also evaluated the multiplicative interaction by adding a product term in the 
logistic model. To further extend our findings, we included EIRA GWAS data and performed 
smoking–GWAS interaction analysis in order to identify any possible signals that might have 
been neglected due to the particular design of the Immunochip. All analyses were performed 
using SAS version 9.3 of the GEIRA program.
147
 
4.2.2 Study II 
Exposure: Snuff use (ever, current and former users versus never users). 
Outcome: Overall, ACPA-positive and ACPA-negative RA. 
Statistical analysis: Association between snuff use and RA risk. 
We calculated the ORs and 95% CIs for the risk of RA overall, as well as for ACPA-positive 
and ACPA-negative RA, associated with snuff use, through unconditional logistic regression 
models. Exposed groups (ever, current and former snuff users) were compared with reference 
group (never users). First we performed the association analysis based on all cases and 
controls, with adjustment for the matching variables (age, gender and residential area), for 
cigarette smoking and for alcohol consumption. We further performed the same analysis with 
matching using conditional logistic regression models. Additional adjustments for education, 
silica exposure, body mass index, the primary genetic risk factor SE and PTPN22 gene did 
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not alter the ORs substantially and were therefore not retained in the final models. Because 
cigarette smoking is the major RA environmental risk factor, and might be an important 
confounder, we also performed an analysis stratified by smoking status (never smokers and 
ever smokers, respectively). We further carried out the above-mentioned analyses among 
men and women separately. SAS version 9.3 was used for all procedures. 
4.2.3 Study III 
Exposures: Amino acid positions 11, 13, 71, 74 at HLA-DRβ1, position 9 at HLA-B and 
position 9 at HLA-DPβ1 (carriers of certain residue versus non-carriers). Genetic risk score 
(GRS, dichotomised at the median of the controls) calculated for each amino acid positions as 
well as for haplotypes (based on the four amino acid positions at HLA-DRB1). Cigarette 
smoking status (never versus ever smokers) and intensity (≤10 versus >10 pack-years of 
smoking). 
Outcome: Seropositive RA (ACPA or RF positive). 
Statistical analysis: Association analysis between amino acids and RA, and between smoking 
and RA; interaction analysis between amino acids GRS/haplotype GRS and smoking in RA 
risk. 
We first calculated the GRS for individual haplotypes by weighting each haplotype based on 
its reported RA risk effect size for Europeans according to data from Raychaudhuri et al.,
56
 
using the following equation: 
𝐺  𝑖  ∑(ln𝑂 ℎ) ∙ ℎ𝑎𝑝𝑙𝑜𝑡𝑦𝑝𝑒ℎ𝑖
𝑛
ℎ= 
 
where 𝐺  𝑖 is a haplotype GRS of individual 𝑖, 𝑂 ℎ is the reported OR of haplotype ℎ and 
ℎ𝑎𝑝𝑙𝑜𝑡𝑦𝑝𝑒ℎ𝑖 is the number of haplotype ℎ in individual 𝑖. 
We also calculated the GRS for each of the amino acid positions using the following 
equation: 
𝐺  𝑘𝑖  ∑(ln𝑂 𝑎𝑘) ∙ 𝐷𝑜𝑠𝑎𝑔𝑒𝑎𝑘𝑖
𝑛
𝑎= 
 
where 𝐺  𝑘𝑖 is a GRS of amino acid position 𝑘 in individual  𝑖, 𝑂 𝑎𝑘 is the reported OR of 
residue 𝑎 at amino acid position 𝑘 (6, 6, 4, 5, 3 and 3 residues at the positions HLA-DRB1 
11, 13, 71, 74, HLA-B 9 and HLA-DPB1 9, respectively) and 𝐷𝑜𝑠𝑎𝑔𝑒𝑎𝑘𝑖 is the imputed 
dosage of residue 𝑎 at amino acid position 𝑘 in individual 𝑖. The GRS was dichotomised at 
the median of the controls for the subsequent interaction analysis.  
We first calculated the OR and 95% CIs of heavy smoking on RA risk by logistic regression 
with adjustment for age, gender and residential area. Associations between the amino acid 
positions and RA risk were evaluated by omnibus test with p-values calculated by log-
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likelihood ratio tests comparing the fit between the null model and full model. We 
subsequently assessed the additive interaction by calculating AP and its 95% CIs, with two 
principal components used as covariates. For each of the amino acid positions‟ GRS, we 
additionally conditioned on GRSs for other amino acid positions to remove the correlation 
effect generated by LD among the amino acid positions. The amino acid positions 11 and 13 
are tightly linked, therefore were not adjusted with regard to each other in the AP model. The 
multiplicative interaction was assessed in a logistic regression by a product term. All analyses 
were performed using SAS version 9.3. 
4.2.4 Study IV 
Exposure: FDRs with versus FDRs without a RA diagnosis. The RA status among FDRs was 
further categorised as RF-positive and RF-negative RA.  
Outcome: Overall RA, seropositive (ACPA or RF) and seronegative (ACPA or RF) RA. 
Statistical analysis: Association between family history of RA and RA risk, with adjustment 
for known genetic and environmental RA risk factors. 
The strength of familial aggregation was evaluated as the OR for the association between the 
“exposure” (RA among FDRs) and the outcome (RA among EIRA subjects), estimated using 
unconditional logistic regression. ORs were first estimated in a crude model with adjustment 
for the design variables (age, gender and residential area) alone, and then in separate adjusted 
models for each (or groups of) risk factor(s). In addition to models for specific covariates, we 
fitted models simultaneously adjusting for individual SNPs, the GRS (calculated based on 
SNPs) and SE, as well as a model adjusting for all environmental factors, and a full model 
adjusting for all covariates. We performed stratified analyses by ACPA status (and RF status) 
in index cases and by RF status in FDRs. All analyses were performed using SAS version 
9.3. 
To accommodate the missingness and the potential selective participation observed among 
controls, multiple imputation (MI) using fully conditional specification models was utilised. 
The imputation model included all the variables in the dataset, with linear and squared terms 
for continuous covariates, and predicted missing values for any variable using existing values 
from other variables. To confirm that the imputation did not bias the results, we also 
performed a complete-case analysis, in which the unadjusted and adjusted model for each 
covariate was fitted only among individuals who had complete information on that particular 
(or group of) covariate(s). 
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5 RESULTS 
5.1 STUDY I 
After QC, we identified a set of 133648 SNPs with an average call rate of 99.7% in 2481 
incident RA cases (1590 ACPA-positive and 891 ACPA-negative cases) and 1856 controls 
from the EIRA study; in the Umeå dataset, 885 RA cases (614 ACPA-positive and 271 
ACPA-negative cases) and 974 controls were available. We did not observe any 
heterogeneity between the EIRA and Umeå data in terms of population stratification (see 
Figure5). 
In the EIRA study using the Immunochip data, a total of 102 non-duplicated SNPs were 
found to significantly interact with smoking in ACPA-positive RA; all were located in the 
HLA region (one from HLA class I and the rest from HLA class II). Among these 102 SNPs, 
three were located in the gene-coding region of chromosome 6 (rs3749966 in C6orf10, and 
rs8084 and rs7192 in HLA-DRA) and four were located in the 3‟ untranslated region (rs7195, 
rs1051336 and rs1041885 in HLA-DRA, and rs10484565 in TAP2), while the rest were from 
intergenic/non-coding regions. The lack of interaction signals outside the HLA region might 
be due to the selective coverage of Immunochip genetic markers. We therefore performed 
GWAS–smoking interaction analysis but no additional signals outside chromosome 6 were 
identified. By contrast, no SNP was found to statistically significantly interact with smoking 
in ACPA-negative RA in any genetic models. Subsequently, we restricted our analyses solely 
to ACPA-positive RA cases and controls. 
We then analysed all the 102 SNPs in the Umeå replication dataset. Only SNPs in the 
replication sample that reached a p-value of less than 0.05, and with the same direction of 
interaction, were considered to be truly replicated. According to these criteria, 51 SNPs from 
the previously identified pairs were replicated. There were no signs of statistically significant 
multiplicative interactions for any of these 102 smoking–SNPs pairs in either dataset, or for 
any of the remaining markers on the Immunochip. 
Given extensive LD in the HLA region, we decided to adjust for HLA-SE alleles on the 
previously identified smoking–SNP pairs to determine possible interaction signals 
independent of HLA-SE. In EIRA, the numbers of interacting SNPs were strongly reduced 
after such adjustment with 12 being identified (after Bonferroni correction) from the co-
dominant model and eight from the recessive model (five overlapping SNPs). Altogether 
eight non-duplicated SNPs (three from the co-dominant model and five from the recessive 
model: rs3104413, rs3129769, rs6931277, rs10484565, rs3129890, rs3129891, rs9268557 
and rs9784858) were successfully replicated in the Umeå sample. All of these were from 
HLA class II region and were in high LD. 
Furthermore, we analysed all the currently identified RA-risk SNPs, based on the published 
results, for interaction with smoking. We did not find any evidence for significant interactions 
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between these non-HLA SNPs and smoking on either the additive or the multiplicative scale 
in any of the three models, using a p-threshold based on adjustment for multiple comparisons.  
Conclusions: Gene–smoking interactions were identified in ACPA-positive, but not ACPA-
negative, RA. Notably, variants in HLA-DRB1 and those in additional genes within the 
MHC class II region, but not in any other gene regions, showed interaction with smoking. 
 
Figure5. Population stratification patterns of Umeå and EIRA samples. 
 
 
Figure6. Manhattan plot using p-values from the interaction analyses between smoking and 
Immunochip SNPs, for ACPA-positive RA (all chromosomes; upper left panel), ACPA-
positive RA (chromosome 6; upper right panel) and ACPA-negative RA (lower panel). 
5.2 STUDY II 
Data were available from a total of 1998 cases and 2252 controls for the snuff–RA 
association analysis. In RA overall, 254 (12.9%) cases were ever moist snuff users and the 
number among controls was 290 (12.9%), resulting in an OR of 1.0 (95% CI: 0.8–1.2). We 
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did not observe any significant associations when the analysis was confined to ACPA-
positive (OR: 1.0, 95% CI: 0.8–1.3) or ACPA-negative RA (OR: 0.9, 95% CI: 0.7–1.2). In 
addition, analyses based on current or past moist snuff use did not reveal any significant 
associations related to the risk of any RA subsets. 
We then performed a stratified analysis on smoking status. Among never-smokers, no 
significant differences in RA risk were observed in the ACPA-positive subset (ever snuff 
users: OR: 1.0, 95% CI: 0.5–1.9; current snuff users: OR: 1.0, 95% CI: 0.5–2.2) as compared 
with the ACPA-negative subset (ever snuff users: OR: 1.0, 95% CI: 0.5–2.0; current snuff 
users: OR 1.5, 95% CI: 0.7–3.3). Of note, the numbers of observations were low, especially 
in the ACPA-negative group. Similarly, among ever-smokers, neither current nor former 
moist snuff use was associated with the risk of ACPA-positive or ACPA-negative RA. 
Because the number of moist snuff users among never smokers was low (5.1%), we decided 
to increase the sample size by incorporating non-regular smokers and former smokers with 
long-term smoking cessation (women >12 years and men >32 years) into the never-smoker 
group. Again, we observed no significant association between current or former snuff use and 
the risk of any type of RA. 
Finally, we performed the above-mentioned analyses among men and women separately. 
Essentially no differences were found, compared with results from both genders combined. 
Conclusions: The use of moist snuff was not associated with the risk of either ACPA-positive 
or ACPA-negative RA, although a moderate protective or harmful effect could not be ruled 
out. The increased risk of RA associated with smoking is most probably not due to nicotine. 
5.3 STUDY III 
Smoking behaviour varied considerably by population, with the Korean cohort showing 
lower prevalence as compared with northern European populations. Heavy smoking (>10 
pack-years), which is known to be a strong environmental risk factor for RA, was 
consistently associated with RA susceptibility in all three populations. 
We imputed HLA classical alleles, amino acid residues and SNPs within the extended MHC 
region from the Immunochip data of 3588 EIRA, 598 NHS and 2125 Korean subjects.  
Concordance rates between the imputed and typed HLA-DRB1 alleles were high (two-digit 
and four-digit resolution: EIRA, 97.3% and 95.0%; NHS, 93.8% and 91.8%; Korean cohort, 
97.4% and 91.4%, respectively). 
We assessed the associations between amino acid positions 11, 13, 71 and 74 in HLA-DRβ1, 
position 9 in HLA-B and position 9 in HLA-DPβ1 and the risk of seropositive RA. 
Consistent with previous reports, the most significant associations were found at amino acid 
positions 11 and 13, in all three populations. Relatively weak or no associations at the other 
positions in HLA-DRβ1, -B and -DPβ1 were identified.  
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The haplotype defined by amino acid positions 11, 13, 71 and 74 is the best model to explain 
the HLA-DRB1 association with RA susceptibility. We subsequently found that RA was 
strongly associated with the dichotomised haplotype GRS in all three populations. When 
evaluating the interaction effect between the dichotomised haplotype GRS and heavy 
smoking, we found significant additive interactions in all three populations (AP (95% CI), p-
value for AP: EIRA, 0.42 (0.31–0.53), 1.16×10−13; NHS, 0.47 (0.19–0.75), 1.07×10−3; 
Korean cohort, 0.80 (0.54–1.06), 9.73×10−14). 
We further evaluated the additive interaction between GRS at each amino acid positions and 
heavy smoking. Significant and consistent synergy was mapped to HLA-DRβ1 amino acid 
positions 11 and 13 in all three populations (AP 0.32–0.72, p-value 1.64×10−4 –1.45×10−5). 
By contrast, there was no consistent interaction effect at the other positions. We also 
calculated multiplicative interaction effects and the results are summarised in Table6. 
Conclusions: The significant gene–environment interaction effects indicate that there may be 
a physical interaction between citrullinated auto-antigens produced by smoking and HLA-DR 
molecules is characterised by the HLA-DRβ1 four-amino acid haplotype, primarily by the 
positions 11 and 13, in addition to the known SE positions 71 and 74. 
Table6. Multiplicative interaction between amino acid GRS and heavy smoking in the risk 
of ACPA-positive RA.  
Amino 
acid GRS 
EIRA NHS Korea 
OR* (95% CI) p-value OR* (95% CI) p-value OR* (95% CI) p-value 
GRS (binary)*pack-year (binary) 
Haplotype 1.09 (0.79–1.50) 0.62 1.77 (0.85–3.66) 0.12 1.77 (0.44–7.09) 0.42 
P11 1.12 (0.79–1.58) 0.53 1.19 (0.89–1.58) 0.23 1.86 (0.68–5.14) 0.23 
P13 1.15 (0.83–1.57) 0.40 1.19 (0.89–1.59) 0.25 2.14 (0.77–5.95) 0.14 
P71 0.93 (0.69–1.24) 0.61 1.19 (0.77–1.82) 0.44 2.01 (0.63–6.41) 0.24 
P74 1.19 (0.89–1.58) 0.24 0.79 (0.52–1.22) 0.29 1.43 (0.19–10.64) 0.73 
P9-B 0.71 (0.50–1.00) 0.50 0.77 (0.35–1.69) 0.52 NA 0.27 
P9-DPB1 1.07 (0.74–1.58) 0.73 0.34 (0.14–0.84) 0.02 NA NA 
GRS (continuous)*pack-year (continuous) 
Haplotype 1.01 (1.01–1.02) <0.0001 1.00 (0.99–1.01) 0.53 1.03 (0.98–1.09) 0.30 
P11 1.01 (1.00–1.01) <0.0001 1.00 (0.99–1.01) 0.69 1.05 (1.00–1.11) 0.03 
P13 1.01 (1.00–1.01) <0.0001 1.00 (0.99–1.01) 0.80 1.04 (0.99–1.09) 0.05 
P71 0.99 (0.99–1.00) 0.03 1.00 (0.99–1.01) 0.75 1.01 (0.97–1.06) 0.58 
P74 1.01 (1.00–1.01) <0.0001 0.99 (0.98–1.01) 0.27 1.08 (1.00–1.16) 0.05 
P9-B 0.99 (0.98–1.01) 0.18 1.00 (0.98–1.02) 0.96 1.32 (0.70–2.49) 0.39 
P9-DPB1 1.01 (1.00–1.02) 0.03 0.97 (0.95–1.00) 0.02 0.75 (0.56–1.01) 0.06 
*: Odds ratios were adjusted for the top five PCs. 
 
5.4 STUDY IV 
A total of 6916 EIRA participants (1828 ACPA-positive cases, 1016 ACPA-negative cases 
and 4072 controls) were available for the study. Overall, 11.9% of ACPA-positive cases had 
at least one FDR with RA; the corresponding figures for ACPA-negative cases and controls 
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were 6.5% and 3.5%, respectively. We observed a higher proportion of FDRs with RA 
among control subjects who had donated blood samples (for genetic measurements) 
compared with those who had not; whereas the opposite pattern was observed among cases. 
To correct for this non-random distribution of missingness, MI was incorporated. 
The crude familial OR for overall RA was 3.05 (95% CI: 2.48–3.76). When sequentially 
adjusting for each environmental risk factor, we observed no appreciable changes in the 
magnitude of familial risk, with ORs ranging from 3.00 to 3.08 (Figure7). However the 
estimates showed a moderate decrease after adjusting for genetic risk factors. Estimates from 
the full model, adjusting for all factors, were slightly lower than those adjusted for genetic 
factors alone; and adjusting for SE and smoking, and their interaction, did not further lower 
the familial risk as compared to adjusting for SE alone. The OR from the full model (2.41) 
was decreased by 21.1% based on using the beta coefficient (log(OR)) scale and by 31.2% 
using the OR scale, as compared with the OR from crude model (3.05). 
When the analyses were separately performed according to ACPA status, we found a stronger 
familial aggregation in ACPA-positive RA (crude OR: 4.10) than in ACPA-negative RA 
(crude OR: 1.61). Although familial OR of ACPA-positive RA did not change considerably 
when environmental factors were included (adjusted OR range: 4.00–4.26), the value 
decreased to some extent when genetic risk factors were included (Figure7). In contrast to 
ACPA-positive RA, the familial OR of ACPA-negative RA was not influenced by either 
genetic or non-genetic factors. Adjusting for the literature-based GRS seems to explain a 
similar proportion of the familial aggregation as adjusting for the individual 76 SNPs for both 
ACPA-positive and ACPA-negative RA. 
A complete-case analysis was also conducted. The estimates were in line with the imputed 
results in that environmental risk factors did not appear to explain the familial risk, while 
genetic factors only explained a small part for ACPA-positive RA. 
Conclusions: Established risk factors only partly provide an explanation for the familial risk 
of RA, suggesting that many (familial) risk factors remain to be identified, in particular for 
seronegative RA. Family history therefore remains an important clinical risk factor for RA. 
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Figure7. OR and 95% CI of the familial risk in overall, ACPA-positive and ACPA-negative 
RA, by adjusting for each identified genetic and environmental risk factor.
  41 
6 DISCUSSION 
Our results have confirmed previous established findings of the significant additive 
interaction effect between smoking and the HLA region, in the aetiology of RA. Furthermore, 
our results have revealed that the increased risk of RA associated with smoking is most 
probably not due to nicotine. With regard to the SE, the amino acid positions 11 and 13 
appear to exert more effect than the traditional 71 and 74 SE positions. Finally, our results 
also indicate that the currently known genetic and environmental risk factors only account for 
a small proportion of RA familial risk, and additional factors need to be identified. 
6.1 GENERAL METHODOLOGICAL CONCERNS 
6.1.1 Power 
Firstly, the “null findings” of the current results will be discussed from an epidemiological 
point of view. In Study I, we did not identify any other SNPs outside chromosome 6 that 
interacted with smoking in ACPA-positive RA. This might be due to a lack of power to 
determine small effect risk alleles. According to our detailed power calculation, using the 
current EIRA sample size and an alpha of 0.05, the power reaches 80% when the effect size 
of smoking is 1.5, the effect size of SNP is 1.1, and the synergistic effect size of smoking–
SNP is 3.3; this might be true for HLA alleles with a strong impact in RA, but may not always 
be the case for other alleles outside HLA with relatively weak magnitudes. Furthermore, in a 
genome-wide setting in which multiple comparisons have been made, it is challenging to 
retain this high level of power when the true alpha needs to be corrected based on the 
numbers of tests performed. Similarly, this may explain the negative findings in ACPA-
negative RA as this subgroup only constitutes 30% of the total patient population, and is 
believed to be heterogeneous rather than homogenous, making it even more likely to be 
underpowered. In Study II, we have estimated the effect of snuff use, with an exposure rate of 
5%, to be around 1.0; this effect size is so small that to rule out a moderate protective (or 
harmful) influence of snuff on RA risk in the order of 1.17 (with an alpha level of 0.05), 
10000 cases and 10000 controls would be needed.  
There are several ways to boost power in epidemiological studies in genome-wide 
settings.
80,148-150
 The most straightforward strategy is to increase sample size, which can be 
implemented by either the involvement of more controls or the combination of datasets from 
several different populations to perform a meta-analysis. The marker imputation technique 
and population stratification analysis have made this strategy even more practical nowadays. 
Where different cohorts have used different genotyping chips, imputation can be applied to 
equate the set of SNPs in each study resulting in a “full” chip.80 Subsequently the studies can 
be combined for each SNP. An alternative way to increase power is to incorporate a multi-
stage design. Because the significance criteria for GWAS are usually quite strict, with 
corrections for multiple comparisons adopted to avoid false-positive findings, power is 
therefore much less than might be imagined. A multi-stage design employs a first stage with a 
small sample size and a low significance level to detect all possible loci of realistic effect 
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size. These small fractions of markers that pass the first stage will be subsequently evaluated 
in an independent sample at the second stage, which is similar in size to or larger than the 
first population. A large efficiency will thus be gained due to the considerably reduced 
number of markers in the second stage. 
Despite our attempts to increase power for Studies I, III and IV, through a two-stage design, a 
combined meta-analysis, allele imputation and missing data imputation, the issue still remains 
a major concern in studies of this type, where hundreds of thousands of markers with weak 
effects are investigated. A better way to improve the insufficiency of power is to collaborate 
universally with the inclusion of all available datasets. The utilisation of consortium data 
would be a reasonable next step. 
6.1.2 Bias 
Bias has been classified traditionally into three broad categories, selection bias, information 
bias and confounding. Selection bias occurs where the exposure frequency does not reflect 
that of the study base. For example, in a screening test, the study subjects usually volunteer to 
be tested, i.e. they select themselves to be screened, whereas the non-participants choose not 
to be screened, thus a selection bias could occur. Recall bias indicates a different pattern with 
regard to the accuracy of information collected, between cases and controls. For example, the 
patients are more likely (or they try) to remember exposures more often (or correctly) (e.g. 
smoking, which might be considered by them as an important RA risk factor) concerning 
their disease compared to the control subjects. Because this over-recall or over-report is 
related to the disease, it tends to result in differential misclassification.
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 The EIRA study has 
several strengths that reduce bias to a large extent. Firstly, the universal free access to the 
medical care system provided in Sweden makes it less likely that people would avoid seeking 
medical help due to financial concerns. Therefore, a relatively complete set of representative 
patient data could be captured. Within the study area, all public as well as most privately run 
rheumatology units were linked to the general welfare system, reporting cases to the EIRA 
database. Its population-based design recruiting incident RA cases, where the estimated 
median duration from first symptom onset to disease diagnosis was 195 days and the 
estimated time between diagnosis and completing the questionnaire was within 12 months, 
makes recall bias less likely than for other study designs (i.e. study using prevalent cases). 
Moreover, the newly diagnosed cases derived from the population share very different traits 
as compared with cases recruited from hospitals (hospital-treated patients), where the latter 
subset might be older, have a more advanced disease course and worse in prognosis, thus the 
likelihood of selection bias is decreased. Similarly, in EIRA, controls were randomly selected 
from a nationwide register, reflecting the characteristics of the study population. Additionally, 
the high participation rates in EIRA (more than 90% of the invited cases and more than 75% 
of the invited controls) further minimised bias. 
However, despite the above-mentioned strengths, we have indeed observed some biased 
behaviour among cases and controls in terms of donating blood. In Study IV, control subjects 
who provided blood samples were more likely to have a family history of RA, whereas the 
  43 
opposite was true for cases. Because analysis of genetic data could only be performed among 
participants who had donated blood samples, such non-random missingness should always be 
taken into account. In Studies I, II and III, we did not observe any differences in the 
distributions of smoking or snuff use among those subjects who did and did not donate blood 
samples. 
Confounding refers to factors that are associated with both the disease and the exposure, yet 
are not an effect of the exposure. In Studies I and III, in which genetic factors have been 
examined, fewer confounding factors need to be considered, as the exposure itself is very 
unlikely to be influenced by other factors. In Study II, in which we analysed the association 
between snuff use and RA, smoking becomes the most important confounder with the largest 
effect. Two methods have been implemented to control for confounding. Firstly, EIRA cases 
and controls were matched by age, gender and residential area, the most common potential 
confounders. Secondly, the sample size of EIRA allowed us to perform a stratified analysis, 
restricted to non-smokers. We have tried to adjust for various other environmental risk factors 
and the results were not affected considerably as compared with adjusting only for matching 
factors and smoking. Of note, although the aim of Study IV is to determine to what extent RA 
familial risk could be explained by current risk factors, the methods used to reach this aim are 
the same as those used to control for confounders. We hypothesised that the familial risk has 
no direct influence on the patients‟ outcome, but rather exerts an effect through a number of 
shared genetic and environmental factors. The well-established EIRA questionnaire, covering 
a wide range of lifestyle-related questions, as well as the genotyping data from blood 
samples, makes it possible to collect data on all the currently known RA risk factors and 
adjust for their effects. After excluding the effects of these “confounders”, we expected to see 
the true remaining familial risk of RA. This was in fact substantial, indicating the major role 
of familial history in RA risk, and suggesting that there are more factors to be identified 
(provided the results were not due to residual confounding from the factors for which we 
adjusted).  
6.1.3 Treatment of Missing Data 
Missing data could be commonly classified as missing completely at random (MCAR), 
missing at random (MAR) and missing not at random (MNAR).
152
 MCAR is the easiest to 
understand: in a dataset, any part of the data is equally likely to be missing as any other part, 
and no relationship is likely between the missing and observed values. The difference 
between MAR and MNAR lies largely in whether the systematic difference between the 
missing values and the observed values can be explained by differences in the observed data. 
For example, depressed people might be less willing to report their incomes, and also have a 
lower income in general. Thus although a high proportion of missing data among depressed 
individuals could be observed, the missingness would be unrelated to income level but rather 
related to their depression; this is an example of MAR. On the other hand, people with a low 
income are less likely to reveal their income; this is an example of MNAR. Unfortunately, in 
reality, it is not possible to distinguish between MAR and MNAR, and sometimes it can also 
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be challenging to recognise MCAR. Therefore, previously a variety of approaches have been 
frequently used to deal with missing data, including replacing missing values with values 
imputed from the observed data (for example, use of the mean of the observed values to 
replace missing data), adopting a missing category indicator and replacing missing values 
with the last measured value (last value carried forward).
153
 None of these approaches is 
statistically valid or sound in general, as they are based on models with implausible 
assumptions. Moreover, these methods impute the missing data only once and then proceed 
to the completed data analysis, which can lead to serious bias, and are thus rarely 
recommended. 
An arbitrary way of dealing with missing values is to simply exclude subjects without values. 
This method was used in Studies I, II and III in which only limited environmental variables 
(smoking or snuff) were used as the main covariates, each with virtually complete 
information. We included subjects with full information on both genotyping and 
environmental data in our analyses. The disadvantage of this method is that we may lose 
power, but the estimates remain most probably unbiased by the absence of data. However, in 
Study IV, in which a wide variety of environmental as well as genetic factors have been 
examined, implementing complete-case analysis would reduce the sample size to half of the 
original size, and thus result in a great loss of precision and power. We therefore employed 
the MI method, which allows individuals with previous incomplete data to be included by 
assigning an imputed value. The imputed values are generated on the basis of existing data, 
irrespective of genetic or environmental factors, based on a Bayesian approach.
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 MI 
accommodates the uncertainty about the missing data by generating several different 
plausible imputed datasets and appropriately combining results obtained from each of them. 
Notably, MI is usually based on the assumptions of MAR and normally distributed data. MI 
might be a superior method of dealing with missing values compared with previous 
approaches that lack plausible assumptions. However, taking into account the MI modelling, 
it might not be surprising that similar patterns of covariate distribution between observed and 
imputed data could be identified after MI, and that given this similar distribution pattern, the 
estimates based on imputed data would be in line with estimates based on complete-case 
analysis. Other practical ways of dealing with missing data include non-response weighting 
and likelihood-based methods, which could provide a good solution to this problem.
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6.2 FINDINGS AND IMPLICATIONS 
6.2.1 HLA Remains an Important Genetic Region in RA Aetiology 
The heritability of RA was firstly (and classically) evaluated through twin studies; the 
increased prevalence of a trait in monozygotic (MZ) twins (who share 100% of their genome 
sequence) compared to dizygotic (DZ) twins (who share 50% of their genome sequence) is a 
powerful way to measure the importance of genetics in the variation of that trait. The 
concordance rate for RA in MZ twins is around 12–15%, approximately four times greater 
than in DZ twins, which indicate that a considerable genetic contribution in RA.
41
 These 
concordance rate data, after being transferred by using quantitative genetic methods, suggest 
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that RA heritability is around 40–60%.41 The estimates have been validated in a recent large 
twin study, showing that ACPA-positive RA heritability is around 39–44%.85 By determining 
MZ twin concordance rates, together with the empirical sibling recurrence risk and the 
observed HLA haplotype sharing by pairs of affected siblings, the contribution of the HLA 
region to RA heritability has been estimated to be 37%.
58
 Consistently, Recent studies using 
genome-wide markers have estimated the identified HLA region variants would explain 
25.4% of ACPA-positive RA heritability.
86,87
 These data together with the results from Study 
I provide clear evidence that the HLA region continues to be an area of major interest in RA 
aetiological studies. 
Extensive investigations of the association between the HLA region and RA have been 
performed, in an effort to clarify the complex hierarchy of risk factors conferred by different 
HLA genotypes. Association studies have demonstrated that, in European populations, all 
HLA-DRB alleles with the SE (01, 04 and 10) provide RA-prone antigen recognition, increase 
the risk of developing ACPA-positive RA and extra-articular manifestations, increase the 
likelihood of progressing into a more severe, erosive, deforming disease and are responsible 
for poor prognosis.
156
 A gene–dose effect could be observed, which is compatible with the 
role of HLA polymorphisms in T cell repertoire shaping.
157
 There has been some debate 
regarding the role of DRB1*15, with a few studies finding a linkage between *15 and 
enhanced ACPA production or circulation.
158,159
 By contrast, DRB1*13 has been shown to 
exert a protective effect.
160
 Some other alleles that are negatively associated with RA include 
*0103, *0402 and *0802. Haplotype analysis revealed that DQ had an important modifying 
influence on the risk of individual SE alleles, resulting in greater disease severity, RF 
positivity and greater degrees of joint deformity. The results of some association studies have 
suggested a direct role for DQ alleles in RA whereas further larger studies have not supported 
this hypothesis.
99
 Conflicting findings have been reported with regard to other susceptible 
loci within the same region independent of SE, including A1-B8-DR3, ZNF311, TNF, DP, 
DO TAP, MICA, VARS2L and others.
156
   
It is clear why some HLA associations, despite having been extensively studied, remain 
controversial. One very important consideration is ethnic or racial differences; another major 
influence comes from LD, a problem that is not unique to RA but affects studies of all 
diseases with strong HLA associations. Several solutions to overcome the strong LD in this 
region have been suggested. A common approach has been to match cases and controls for 
the haplotypes at HLA-DRB1, and to use large datasets to obtain sufficient power. Other 
solutions include using the within-family association, or pooling on the basis of carriage of a 
specific DRB1 allele. 
Before 2012, HLA alleles were believed to be exclusively associated with ACPA-positive 
RA. Then, a well-powered study combining data from several Caucasian populations 
identified and confirmed the association between SE and ACPA-negative RA.
161
 Despite 
adjustment for the heterogeneity of ACPA-negative RA in the study, as well as validation 
using clinically homogeneous ACPA-negative cases, i.e. CCP-negative RA cases which were 
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also negative for four different ACPAs (α-enolase, vimentin, fibrinogen and collagen type II), 
the role of this identified association and its possible restriction to specific subtypes of 
ACPA-negative RA remain to be determined. It also remains a challenge to identify 
interactions or epistasis among ACPA-negative disease subsets, firstly because ACPA-
negative RA is likely to be a mixture of arthritis-related symptoms rather than a homogenous 
disease group; and secondly because the sample size is far smaller for ACPA-negative 
compared to ACPA-positive RA cases; and finally, so far, no strong or consistent 
environmental or genetic risk factors have been found in ACPA-negative RA, making it even 
more difficult to identify interaction effects without any main association effects. Therefore, 
further effort is needed to collect large numbers of “pure” ACPA-negative patients, and to 
identify pathogenically relevant subsets within this population of RA patients. 
6.2.2 Interactions outside the HLA region Remain to be Identified 
Despite the strong linkage between HLA and RA, the presence of HLA alleles is neither 
necessary nor sufficient for occurrence of the disease. The remaining risk could be ascribed to 
other regions. Moreover, previously published data using the candidate gene approach have 
shown that smoking interacts with genes from other chromosomes, with one well-established 
example being PTPN22.
142
 A possible way to identify the potential signals could be through 
incorporating biological mechanisms to connect specific genes or gene pathways to specific 
environmental factors. The interaction between smoking and the HLA region is compatible 
with the arthritogenic antigen-presentation theory. Alcohol consumption might exert its 
effects through alternative gene pathways.
162
 For example, results from studies in mice 
suggest that: 1) levels of tumour necrosis factor and interleukin-6 (two pro-inflammatory 
molecules implicated in RA) can be reduced by adding a low dose of ethanol to the drinking 
water; 2) NSAIDs cause gastric/gastrointestinal pain and bleeding while DMARDs worsen 
liver problems, and both effects can be exacerbated by alcohol; and 3) the cytokine–hormone 
axis might be another source of genetic pathways when considering the alcohol–gene 
interaction. More gene–gene and gene–environment interactions remain to be revealed, 
although they might be weaker in magnitude than the smoking–SE interaction. One very 
interesting possibility could be to explore the roles of some well-recognised inhalation 
factors, and their synergistic effect with genes, as these factors share the same exposure 
pathways with smoking: the airways and the lung. Examples of such factors could include 
textile dust, silica dust, air pollutants and solvents. 
6.2.3 Smoking Is a Major Preventable Factor for RA 
Smoking is a well-characterised inhalation exposure, and the smoking–RA association is the 
most recognised link between the environment and the aetiology of the disease. A large 
number of studies have demonstrated adverse effects of smoking in either RA incidence or 
prognosis.
105
 
106
 In line with previous findings, we confirmed a comparable risk effect of 
smoking in ACPA-positive RA among one Asian and three European populations from 
Studies I and III. In Study II we also assessed the influence of smoking cessation on RA risk; 
consistent with previous findings, the effect of smoking started to return to baseline after 12 
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years of cessation among women and after 32 years among men, indicating a reduction but 
not elimination of the risk. The excess fraction (EF) of cases attributable to smoking has been 
calculated as an indicator of the relevance of smoking as a risk factor for RA in the 
population of Sweden. It was concluded that EF attributable to smoking was 35% for ACPA-
positive RA and 20% for RA overall; in addition, among ACPA-positive RA cases with 
double SE alleles, 55% could be attributable to smoking.
10
 Given that EF is highly dependent 
on the prevalence of exposure, it may be higher in other populations with higher smoking 
rates than in Sweden, a country with a low prevalence of smoking. 
From a public health perspective, the additive interaction between smoking and genes 
provides optimal information in terms of disease prevention and intervention: if the joint 
effect of two factors is higher than the sum of their single effects, then reduction of either 
factor would also reduce the risk of the other in producing disease.
163
 Taking into account the 
profound synergistic effect, as well as that it takes more than 10 years for the main effect of 
smoking to return to the baseline level, it is important to advise RA patient not to start 
smoking, to smoke less or to quit as soon as possible. A more sensible practical strategy 
could be to educate the families, and in particular the children, of RA patients about the 
importance of not smoking. 
In Study II, we found no association between snuff use and the risk of RA. We conclude that 
constituents in the cigarette smoke other than nicotine, most probably many noxious 
substances that may cause irritation of the airways and activation of innate as well as adaptive 
immunity, are likely to be involved in the pathogenesis of RA. However, we could not rule 
out a minor effect (harmful or protective) of nicotine in RA, and large studies are warranted 
to elucidate its association with RA. However, we do not recommend that RA patients use 
snuff as a substitute for cigarette smoking, because snuff is a demonstrated risk factor for oral 
cancer. 
6.2.4 Reconsideration of the Definition of SE 
The SE hypothesis was first proposed by Gregersen et al. almost 30 years ago,
43
 which may 
no longer be the best or the most complete model to describe RA risk in light of the dramatic 
changes in technology and biology that have since occurred. Attempts have been made to 
redefine SE. In 2005, Sophie Du Montcel et al. proposed a new classification of HLA-DRB1 
alleles,
164
 according to which, the risk of developing RA depends on whether the RAA 
epitope is present at positions 72–74 but is also modulated by the amino acids in positions 70 
and 71. The KRAA motif at positions 71–74 confers the highest RA susceptibility, and the 
RRRAA or QRRAA motifs confer an intermediate risk.
164
 This new classification was 
subsequently tested and validated by Laetitia Michou et al., in an independent sample of 100 
Caucasian RA trio families,
165
 as well as by Thomas Barnetche et al., in 759 cases and 789 
controls with different ethnic backgrounds.
166
 However, this new classification was restricted 
to traditional SE with no novel positions involved. In 2012, Raychaudhuri et al. applied an 
imputation approach to SNP data from a GWAS meta-analysis in 5018 seropositive RA cases 
and 14974 controls, and demonstrated that the risk of RA associated with HLA-DRB1 gene 
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correlates most strongly with the amino acid residue in position 11 (or 13) located at the 
bottom of the surface of the DRβ1 antigen-binding groove.56 The traditional SE positions 71 
and 74, were also but not as strongly associated independently with RA susceptibility. In 
addition, independent RA risk alleles in HLA-B and HLA-DPB1 were found. No further 
association signals were identified within the HLA when controlled for all these independent 
effects from the five amino acid positions. Results from our Study III support and strengthen 
the finding of Raychaudhuri et al. that the most profound interaction effect with smoking was 
on the amino acid position 11 or 13, in addition to the amino acid positions 70–74, and that 
the haplotype based on amino acids 11, 13, 71 and 74 had more pathogenic effect in the 
binding and presentation of smoking-induced auto-antigen like ACPAs. Based on these 
results, the HLA-DRB1 association and the SE-smoking interaction appear to be best 
explained by the new haplotype, but biological explanations are still needed. 
6.2.5 Uncharacterised Genetic Variance Remains to be Discovered 
The results from Study IV suggest that all the currently identified RA risk factors together 
only explain a small proportion of the total susceptibility. It has been estimated that hundreds 
of common risk alleles are likely to exist but remain undiscovered to date, and that those 
uncharacterised SNP associations throughout the genome, together with known risk alleles, 
would explain in total 36% of RA disease risk.
87
 Therefore, current SNP associations only 
account for half of the estimated RA heritability. Sequencing experiments might have the 
potential to identify causal variants across the entire allele frequency range, in particular for 
low frequency alleles. A recent epigenome-wide association study in 354 ACPA-positive RA 
patients and 337 control subjects identified 10 differentially methylated positions potentially 
mediating genetic risk in RA, nine of which were located within MHC over four gene regions 
and the only one outside of MHC was located at chromosome 6.
167
 These findings, together 
with our results, further indicate a great potential for the identification of genetic or epigenetic 
variations outside of the MHC; within the MHC, a challenging task for future investigations 
will be to determine which specific immune reactions are related to smoking and specific 
MHC molecular structures. 
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6.3 FUTURE DIRECTIONS 
- Further identification of causal genetic variants and their characterisation, and 
incoporation of epigenetic results. Development of computational tools to calculate 
genome-wide interactions taking into account all the possible combinations of current 
markers available from the CHIP (not only one-to-one interaction, but also N-to-N 
interaction). 
- Investigation of gene–gene and gene–environment interactions involving 
environmental risk factors other than smoking, such as lifestyle-related factors (e.g. 
alchol consumption, body mass index and others). In particular, inhalable factors (e.g. 
silica dust, solvent exposure and textile dust) and airway infections (e.g. influzena) 
should be considered.  
- Accurate risk prediction in susceptible individuals through the combination of 
currently identified genetic markers, lifestyle-related factors, occupational hazards 
and serological measurements. Accurate prediction of disease heritability in 
susceptible individuals using their familial risks and genotypes, and information from 
relatives. 
- Utilisation of consortium data and collaborative efforts involving multiple populations 
to increase the power of current research. 
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